Crispr-cas systems and methods for altering expression of gene products

JP2024088668A5Pending Publication Date: 2024-11-26THE BROAD INST INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024050615
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2013-10-15
Filing Date
2024-03-27
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

There is a need for alternative and robust genome engineering techniques that facilitate targeting of multiple locations within the nuclear genome, as existing methods like designer zinc fingers and TALEs are cumbersome and require customized proteins.

Method used

The CRISPR/Cas system uses a short RNA molecule to program the Cas enzyme for specific DNA targeting, eliminating the need for customized proteins and enabling versatile sequence targeting.

Benefits of technology

This approach simplifies genome editing methodologies, accelerates the classification and mapping of genetic factors associated with biological functions and diseases, and allows for precise modification of gene expression in eukaryotic cells, including human cells.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide: systems, methods and compositions for altering expression of target gene sequences and related gene products; vectors and vector systems some of which encode one or more components of a CRISPR complex and methods for designing and using such vectors; and methods for directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.SOLUTION: Disclosed herein is a method for altering the expression of one or more gene products comprising: introducing an engineered and not-naturally occurring CRISPR-Cas system comprising Cas protein and one or more guide RNAs targeting the DNA molecules in a cell containing and expressing the DNA molecules encoding the one or more gene products, thereby the one or more guide RNAs target the genomic loci of the DNA molecules encoding the one or more gene products and the Cas protein cleaves the genomic loci of the DNA molecules encoding the one or more gene products, which results in altering expression of the one or more gene products, where the Cas protein and the guide RNAs do not naturally occur together.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] RELATED APPLICATIONS AND INCORPORATION BY REFERENCE This application claims priority to U.S. Provisional Patent Application No. 61 / 842,322 and U.S. Patent Application No. 14 / 054,414, entitled CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS, filed July 2, 2013 and October 15, 2013, respectively, bearing the Broad reference BI-2011 / 008A. Priority is also claimed to U.S. Provisional Patent Applications Nos. 61 / 736,527, 61 / 748,427, 61 / 791,409, and 61 / 835,931, all of which are entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCES, all of which are incorporated herein by reference in their entirety, all of which are incorporated herein by reference in their entirety. MANIPULATION, which were filed on December 12, 2012, January 2, 2013, March 15, 2013, and June 17, 2013, respectively. Reference is made to U.S. Provisional Patent Applications Nos. 61 / 758,468; 61 / 769,046; 61 / 802,174; 61 / 806,375; 61 / 814,263; 61 / 819,803 and 61 / 828,130, each entitled ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, which were filed on Jan. 30, 2013; Feb. 25, 2013; Mar. 15, 2013; Mar. 28, 2013; Apr. 20, 2013; May 6, 2013 and May 28, 2013, respectively. Reference is also made to U.S. Provisional Patent Applications Nos. 61 / 835,936, 61 / 836,127, 61 / 836,101, 61 / 836,080, and 61 / 835,973, each filed on June 17, 2013.

[0002] The above applications, and all documents cited in those applications or during their prosecution ("application cited documents") and all documents cited or referenced in those application cited documents, as well as all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in the herein cited documents, are hereby incorporated by reference and may be used in the practice of the present invention, together with any manufacturer's instructions, manuals, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein. More specifically, all references are incorporated by reference to the extent that each individual document is individually and specifically indicated to be incorporated by reference.

[0003] The present invention relates generally to systems, methods and compositions used for controlling gene expression, including sequence targeting, e.g., genomic perturbation or gene editing, which may use vector systems relating to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and its components.

[0004] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made with Government support under NIH Pioneer Award DP1MH100706 awarded by the National Institutes of Health. The Government has certain rights in this invention. [Background technology]

[0005] Recent advances in genome sequencing technology and analysis methods have significantly accelerated the ability to classify and map genetic factors related to a diverse range of biological functions and diseases.Accurate genome targeting technology is required to enable the systematic reverse engineering of causal genetic mutations by enabling the selective perturbation of individual genetic elements, and to advance synthetic biology, biotechnology and pharmaceutical applications.Genome editing technology, such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases, can be used to produce targeted genome perturbations, but there is still a need for new genome engineering technology that is inexpensive, easy to set up, scalable, and easy to target multiple locations in eukaryotic genomes. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] U.S. Pat. No. 4,873,316 Summary of the Invention [Problem to be solved by the invention]

[0007] There is an urgent need for alternative and robust systems and techniques for sequence targeting with various applications. The present invention addresses this need and provides related advantages. CRISPR / Cas or CRISPR-Cas systems (both terms are used interchangeably throughout this application) do not require the generation of customized proteins to target specific sequences, but a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target, in other words, the Cas enzyme can be recruited to a specific DNA target using said short RNA molecule. The addition of CRISPR-Cas systems to the repertoire of genome sequencing technologies and analysis methods significantly simplifies the methodology and accelerates the ability to classify and map genetic factors related to a diverse range of biological functions and diseases. To effectively utilize CRISPR-Cas systems for genome editing without adverse effects, it is important to understand the engineering and optimization aspects of these genome engineering tools, which are an aspect of the claimed invention. [Means for solving the problem]

[0008] In one aspect, the present invention provides a method for altering or modifying the expression of one or more gene products, which may include introducing an engineered non-naturally occurring CRISPR-Cas system into a cell that contains and expresses a DNA molecule encoding one or more gene products, which may include a Cas protein and one or more guide RNAs that target the DNA molecule, whereby the one or more guide RNAs target the genomic locus of the DNA molecule encoding the one or more gene products, and the Cas protein cleaves the genomic locus of the DNA molecule encoding the one or more gene products, thereby altering or modifying the expression of the one or more gene products; the Cas protein and the guide RNA together provide a non-naturally occurring method. The present invention encompasses that the expression of two or more gene products can be altered or modified. The present invention further encompasses that the guide RNA comprises a guide sequence fused to a tracr sequence. In a preferred embodiment, the cell is a eukaryotic cell, in a more preferred embodiment, the cell is a mammalian cell, and in an even more preferred embodiment, the mammalian cell is a human cell. The present invention also encompasses that the Cas protein may include one or more nuclear localization signals (NLS). In some embodiments, the Cas protein is a type II CRISPR enzyme. In some embodiments, the Cas protein is a Cas9 protein. In some embodiments, the Cas9 protein is S. pneumoniae, S. pyogenes, or S. thermophilus Cas9, including mutant Cas9 from these organisms. The protein can be a Cas9 homolog or ortholog. In some embodiments, the Cas protein is codon-optimized for expression in eukaryotic cells. In some embodiments, the Cas protein directs cleavage of one or two strands at the location of the target sequence. In a further aspect of the invention, the expression of a gene product is decreased, and the gene product is a protein. The invention encompasses that introduction into a cell is by a delivery system, which can include a viral particle, a liposome, electroporation, microinjection, or conjugation.

[0009] In another embodiment, the present invention provides a method for altering or modifying the expression of one or more gene products, comprising: introducing into a cell that contains and expresses a DNA molecule encoding one or more gene products, a) a first regulatory element operably linked to one or more CRISPR-Cas system guide RNAs that hybridize with a target sequence in the genomic locus of the DNA molecule encoding the one or more gene products, and b) a second regulatory element operably linked to a Cas protein, components (a) and (b) being on the same or different vectors of the system, whereby the guide RNA targets the genomic locus of the DNA molecule encoding the one or more gene products, and the Cas protein cleaves the genomic locus of the DNA molecule encoding the one or more gene products, thereby altering or modifying the expression of the one or more gene products; the Cas protein and the guide RNA together may comprise one or more non-naturally occurring vectors. The present invention encompasses that the expression of two or more gene products can be altered or modified. The present invention further encompasses that the guide RNA comprises a guide sequence fused to a tracr sequence. In a preferred embodiment, the cell is a eukaryotic cell, in a more preferred embodiment, the cell is a mammalian cell, and in an even more preferred embodiment, the mammalian cell is a human cell. The present invention also encompasses that the vector of the system may further comprise one or more NLS. In some embodiments, the Cas protein is a type II CRISPR system enzyme. In some embodiments, the Cas protein is a Cas9 protein. In some embodiments, the Cas9 protein is a S. pneumoniae, S. pyogenes, or S. thermophilus Cas9, and may include mutant Cas9 from these organisms. The protein may be a Cas9 homolog or ortholog. In some embodiments, the Cas protein is codon-optimized for expression in eukaryotic cells. In some embodiments, the Cas protein directs cleavage of one or two strands at the location of the target sequence.In a further embodiment of the invention, the expression of a gene product is decreased, the gene product being a protein. The invention encompasses that introduction into a cell is by a delivery system which may include a viral particle, a liposome, electroporation, microinjection or conjugation.

[0010] The present invention also provides an engineered non-naturally occurring vector system that includes a) a first regulatory element operably linked to one or more CRISPR-Cas system guide RNAs that hybridize with a target sequence in a genomic locus of a DNA molecule that encodes one or more gene products, and b) a second regulatory element operably linked to a Cas protein, where components (a) and (b) are on the same or different vectors of the system, whereby the guide RNA targets the genomic locus of a DNA molecule that encodes one or more gene products in a cell, and the Cas protein cleaves the genomic locus of a DNA molecule that encodes one or more gene products, whereby the expression of one or more gene products is altered or modified; the Cas protein and the guide RNA together may include one or more non-naturally occurring vectors. The present invention encompasses that the expression of two or more gene products can be altered or modified. The present invention further encompasses that the guide RNA comprises a guide sequence fused to a tracr sequence. In a preferred embodiment, the cell is a eukaryotic cell, in a more preferred embodiment, the cell is a mammalian cell, and in an even more preferred embodiment, the mammalian cell is a human cell. The present invention also encompasses that the vector of the system may further comprise one or more NLS. In some embodiments, the Cas protein is a type II CRISPR system enzyme. In some embodiments, the Cas protein is a Cas9 protein. In some embodiments, the Cas9 protein is S.pneumoniae, S.pyogenes, or S.thermophilus Cas9, and may include mutant Cas9 from these organisms. The protein may be a Cas9 homolog or ortholog. In some embodiments, the Cas protein is codon-optimized for expression in eukaryotic cells. In some embodiments, the Cas protein directs the cleavage of one or two strands at the location of the target sequence. In a further aspect of the present invention, the expression of a gene product is reduced, and the gene product is a protein.The present invention encompasses introduction into a cell by a delivery system which may include viral particles, liposomes, electroporation, microinjection or conjugation.

[0011] In yet another aspect, the present invention can include a Cas protein and one or more guide RNAs targeting a genomic locus of a DNA molecule encoding one or more gene products in a cell, the Cas protein cleaving the genomic locus of the DNA molecule encoding one or more gene products, thereby altering or modifying the expression of the one or more gene products; the Cas protein and the guide RNA together provide a non-naturally occurring engineered programmable non-naturally occurring CRISPR-Cas system. The present invention encompasses that the expression of two or more gene products can be altered or modified. The present invention further encompasses that the guide RNA comprises a guide sequence fused to a tracr sequence. In a preferred embodiment, the cell is a eukaryotic cell, in a more preferred embodiment, the cell is a mammalian cell, and in an even more preferred embodiment, the mammalian cell is a human cell. The present invention also encompasses that the CRISPR-Cas system can further include one or more NLSs. In some embodiments, the Cas protein is a type II CRISPR system enzyme. In some embodiments, the Cas protein is a Cas9 protein. In some embodiments, the Cas9 protein is S. pneumoniae, S. pyogenes, or S. thermophilus Cas9, and may include mutant Cas9 from these organisms. The protein may be a Cas9 homolog or ortholog. In some embodiments, the Cas protein is codon-optimized for expression in eukaryotic cells. In some embodiments, the Cas protein directs cleavage of one or two strands at the location of the target sequence. In a further aspect of the invention, the expression of a gene product is decreased, and the gene product is a protein. The invention encompasses that introduction into the cell is by a delivery system, which may include a viral particle, a liposome, electroporation, microinjection, or conjugation.

[0012] In one aspect, the present invention provides a vector system comprising one or more vectors.In some embodiments, the system comprises: (a) a first regulatory element operably linked to tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of tracr mate sequence, where the guide sequence directs the sequence-specific binding of CRISPR complex to target sequence in eukaryotic cells, and the CRISPR complex comprises (1) the guide sequence hybridized to target sequence, and (2) the CRISPR enzyme complexed with the tracr mate sequence hybridized to tracr sequence; and (b) a second regulatory element operably linked to the enzyme coding sequence encoding the CRISPR enzyme comprising a nuclear localization sequence; components (a) and (b) are on the same or different vectors of the system.In some embodiments, component (a) further comprises the tracr sequence downstream of tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, each of the two or more guide sequences directs the sequence-specific binding of CRISPR complex to different target sequences in eukaryotic cells when expressed. In some embodiments, the system comprises a third regulatory element, such as a tracr sequence under the control of a polymerase III promoter. In some embodiments, the tracr sequence shows at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% sequence complementarity along the length of the tracr mate sequence when optimally aligned. Determining optimal alignment is within the skill of a person skilled in the art. For example, there are public and commercially available alignment algorithms and programs, such as, but not limited to, ClustalW, Smith-Waterman in matlab, Bowtie, Geneious, Biopython and SeqMan. In some embodiments, the CRISPR complex comprises one or more nuclear localization sequences of sufficient strength to drive accumulation of said CRISPR complex in a detectable amount in the nucleus of a eukaryotic cell.Without being bound by theory, it is believed that nuclear localization sequences are not necessary for CRISPR complex activity in eukaryotes, but including such sequences improves the activity of the system, especially for targeting nucleic acid molecules in the nucleus. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme. In some embodiments, the Cas9 enzyme is S.pneumoniae, S.pyogenes, or S.thermophilus Cas9, and may include mutant Cas9 from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in eukaryotic cells. In some embodiments, the CRISPR enzyme directs the cleavage of one or two strands at the location of the target sequence. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or 10-30, or 15-25, or 15-20 nucleotides in length. In general, and throughout this specification, the term "vector" refers to a nucleic acid molecule that can transport another nucleic acid to which it is linked. Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules that contain one or more free ends and no free ends (e.g., circular); nucleic acid molecules that contain DNA, RNA, or both; and various other polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be inserted, for example, by standard molecular cloning techniques. Another type of vector is a viral vector, in which viral-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g., retroviruses, replication-defective retroviruses, adenoviruses, replication-defective adenoviruses, and adeno-associated viruses).Viral vectors also include polynucleotides carried by viruses for transfection into host cells. Some vectors can replicate autonomously in the host cell into which they are introduced (e.g., bacterial vectors with bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell upon introduction into the host cell, and are thereby replicated together with the host genome. In addition, some vectors can direct the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". Common expression vectors useful in recombinant DNA technology are often in the form of plasmids.

[0013] A recombinant expression vector may contain the nucleic acid of the present invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector may be selected based on the host cell to be used for expression and contains one or more regulatory elements operably linked to the nucleic acid sequence to be expressed. In the recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to a regulatory element in a manner that allows expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell).

[0014] The term "regulatory element" is intended to include promoters, enhancers, internal ribosome entry sites (IRES), and other expression control elements (e.g., transcription termination signals, e.g., polyadenylation signals and polyU sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of a nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Tissue-specific promoters can direct expression primarily in a desired tissue of interest, e.g., muscle, nerve cells, bone, skin, blood, specific organs (e.g., liver, pancreas), or specific cell types (e.g., lymphocytes). Regulatory elements can also direct expression in a time-dependent manner, such as cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue or cell type specific. In some embodiments, the vector comprises one or more polIII promoters (e.g., 1, 2, 3, 4, 5 or more polIII promoters), one or more polII promoters (e.g., 1, 2, 3, 4, 5 or more polII promoters), one or more polI promoters (e.g., 1, 2, 3, 4, 5 or more polI promoters), or a combination thereof. Examples of polIII promoters include, but are not limited to, U6 and H1 promoters.Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter. The term "regulatory element" also encompasses enhancer elements, such as the WPRE; CMV enhancer; the R-U5' segment in the LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), p. 466-472, 1988); the SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the desired expression level, and the like. The vector can be introduced into a host cell to produce a protein, including a transcript, a fusion protein, or a peptide, or a peptide (e.g., a clustered regularly interspaced short repeats (CRISPR) transcript, a protein, an enzyme, a mutant thereof, a fusion protein thereof, and the like) encoded by the nucleic acid described herein.

[0015] Advantageous vectors include lentiviruses and adeno-associated viruses, and such vector types can also be selected for targeting specific cell types.

[0016] In one aspect, the present invention provides a eukaryotic host cell comprising: (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence, the guide sequence directing sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, the CRISPR complex comprising (1) a guide sequence hybridized to a target sequence, and (2) a CRISPR enzyme complexed with a tracr mate sequence hybridized to a tracr sequence; and / or (b) a second regulatory element operably linked to an enzyme coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the host cell comprises components (a) and (b). In some embodiments, components (a), (b), or (a) and (b) are stably integrated into the genome of the host eukaryotic cell. In some embodiments, component (a) further comprises a tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, each of the two or more guide sequences directing sequence-specific binding of the CRISPR complex to a different target sequence in the eukaryotic cell when expressed. In some embodiments, the eukaryotic host cell further comprises a third regulatory element operably linked to the tracr sequence, for example, a polymerase III promoter. In some embodiments, the tracr sequence shows at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% sequence complementarity along the length of the tracr mate sequence when optimally aligned. The enzyme can be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in eukaryotic cells. In some embodiments, the CRISPR enzyme directs one or two strand cleavage at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter.In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or 10-30, or 15-25, or 15-20 nucleotides in length. In one aspect, the invention provides a non-human eukaryotic organism comprising a eukaryotic host cell according to any of the described embodiments; preferably a multicellular eukaryotic organism. In another aspect, the invention provides a eukaryotic organism comprising a eukaryotic host cell according to any of the described embodiments; preferably a multicellular eukaryotic organism. The organism in some embodiments of these aspects may be an animal; for example, a mammal. The organism may also be an arthropod, for example, an insect. The organism may also be a plant. Additionally, the organism may be a fungus.

[0017] In one aspect, the present invention provides a kit comprising one or more of the components described herein. In some embodiments, the kit comprises a vector system and instructions for use of the kit. In some embodiments, the vector system comprises (a) a first regulatory element operably linked to a tracr mate sequence and one or more insertion sites for inserting one or more guide sequences upstream of the tracr mate sequence (the guide sequence, when expressed, directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, the CRISPR complex comprising (1) a guide sequence hybridized to a target sequence, and (2) a CRISPR enzyme complexed with the tracr mate sequence hybridized to the tracr sequence); and / or (b) a second regulatory element operably linked to an enzyme coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence. In some embodiments, the kit comprises components (a) and (b) on the same or different vectors of the system. In some embodiments, component (a) further comprises a tracr sequence downstream of the tracr mate sequence under the control of the first regulatory element. In some embodiments, component (a) further comprises two or more guide sequences operably linked to the first regulatory element, each of the two or more guide sequences directing sequence-specific binding of the CRISPR complex to a different target sequence in eukaryotic cells when expressed. In some embodiments, the system further comprises a third regulatory element operably linked to the tracr sequence, for example, a polymerase III promoter. In some embodiments, the tracr sequence shows at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, the CRISPR enzyme comprises one or more nuclear localization sequences of sufficient strength to drive the accumulation of the CRISPR enzyme in a detectable amount in the nucleus of the eukaryotic cell. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 enzyme.In some embodiments, the Cas9 enzyme is S. pneumoniae, S. pyogenes, or S. thermophilus Cas9, and may include mutant Cas9s derived from those organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the CRISPR enzyme is codon-optimized for expression in eukaryotic cells. In some embodiments, the CRISPR enzyme directs cleavage of one or two strands at the location of the target sequence. In some embodiments, the CRISPR enzyme lacks DNA strand cleavage activity. In some embodiments, the first regulatory element is a polymerase III promoter. In some embodiments, the second regulatory element is a polymerase II promoter. In some embodiments, the guide sequence is at least 15, 16, 17, 18, 19, 20, 25 nucleotides, or 10-30, or 15-25, or 15-20 nucleotides in length.

[0018] In one aspect, the present invention provides a method for modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises binding a CRISPR complex to a target polynucleotide to cause cleavage of the target polynucleotide, thereby modifying the target polynucleotide, the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence in the target polynucleotide, the guide sequence being in turn bound to a tracr mate sequence hybridized to a tracr sequence. In some embodiments, the cleavage comprises cleaving one or two strands at the location of the target sequence by the CRISPR enzyme. In some embodiments, the cleavage results in a decrease in transcription of a target gene. In some embodiments, the method further comprises repairing the cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, the repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of the target polynucleotide. In some embodiments, the mutation results in one or more amino acid changes in a protein expressed from a gene comprising a target sequence. In some embodiments, the method further comprises delivering one or more vectors to the eukaryotic cell, the one or more vectors driving expression of one or more of CRISPR enzyme, guide sequence linked to tracr mate sequence, and tracr sequence. In some embodiments, the vector is delivered into the eukaryotic cell in the subject. In some embodiments, the modification is performed in the eukaryotic cell in cell culture. In some embodiments, the method further comprises isolating the eukaryotic cell from the subject before the modification. In some embodiments, the method further comprises returning the eukaryotic cell and / or cells derived therefrom to the subject.

[0019] In one aspect, the present invention provides a method for modifying the expression of polynucleotide in eukaryotic cells.In some embodiments, the method comprises: binding CRISPR complex to polynucleotide, such that said binding leads to increased or decreased expression of said polynucleotide; CRISPR complex comprises CRISPR enzyme complexed with guide sequence hybridized to target sequence in said polynucleotide, said guide sequence is then bound to tracr mate sequence, which hybridizes to tracr sequence.In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, said one or more vectors drive the expression of one or more of CRISPR enzyme, guide sequence bound to tracr mate sequence, and tracr sequence.

[0020] In one aspect, the present invention provides a method for generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, the disease gene is any gene associated with an increased risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, the one or more vectors driving expression of one or more of a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence, and (b) binding a CRISPR complex to a target polynucleotide to cause cleavage of a target polynucleotide within the disease gene, the CRISPR complex comprising (1) a guide sequence hybridized to a target sequence within a target polynucleotide, and (2) a CRISPR enzyme complexed with a tracr mate sequence hybridized to a tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, the cleavage comprises cleavage of one or both strands at the location of the target sequence by the CRISPR enzyme. In some embodiments, the cleavage results in a decrease in transcription of the target gene. In some embodiments, the method further comprises repairing the cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein the repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of the target polynucleotide. In some embodiments, the mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence.

[0021] In one aspect, the present invention provides a method for developing a bioactive agent that modulates a cell signaling event associated with a disease gene. In some embodiments, the disease gene is any gene associated with an increased risk of having or developing a disease. In some embodiments, the method includes: (a) contacting a test compound with a model cell of any one of the described embodiments; and (b) detecting a change in a readout that indicates a reduction or increase in a cell signaling event associated with the mutation in the disease gene, thereby developing the bioactive agent that modulates the cell signaling event associated with the disease gene.

[0022] In one aspect, the present invention provides a recombinant polynucleotide comprising a guide sequence upstream of a tracr mate sequence, wherein the guide sequence, when expressed, directs the sequence-specific binding of CRISPR complex to the corresponding target sequence present in eukaryotic cells.In some embodiments, the target sequence is a viral sequence present in eukaryotic cells.In some embodiments, the target sequence is a proto-oncogene or oncogene.

[0023] In one aspect, the present invention provides a method for selecting one or more cells by introducing one or more mutations in a gene in one or more cells, comprising: introducing one or more vectors into the cell, the one or more vectors driving expression of one or more of CRISPR enzyme, guide sequence linked to tracr mate sequence, tracr sequence, and editing template; the editing template comprises one or more mutations that stop CRISPR enzyme cleavage; allowing the editing template to homologously recombine with a target polynucleotide in the cell to be selected; allowing a CRISPR complex to bind to the target polynucleotide to cause cleavage of the target polynucleotide in the gene, the CRISPR complex comprising (1) a guide sequence hybridized to a target sequence in the target polynucleotide, and (2) a CRISPR enzyme complexed with a tracr mate sequence hybridized to a tracr sequence, and the binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing the selection of one or more cells into which one or more mutations have been introduced. In some embodiments, the CRISPR enzyme is a type II CRISPR system enzyme. In some embodiments, the CRISPR enzyme is a Cas9 protein. In some embodiments, the Cas9 protein is S. pneumoniae, S. pyogenes, or S. thermophilus Cas9, and may include mutant Cas9 from these organisms. The enzyme may be a Cas9 homolog or ortholog. In some embodiments, the enzyme is codon-optimized for expression in eukaryotic cells. In some embodiments, the enzyme directs cleavage of one or two strands at the location of the target sequence. In a preferred embodiment, the CRISPR enzyme is Cas9. In another preferred embodiment of the present invention, the cell to be selected may be a eukaryotic cell. Aspects of the present invention allow for the selection of defined cells without requiring a selection marker or a two-step process that may include a counterselection system.

[0024] The embodiments of the present invention encompassed site-specific gene knockout in endogenous genomes: the present invention is advantageous over the use of zinc finger and TAL effector-based site-specific nuclease technology, because it does not require complex design and can be used to knock out multiple genes in the same genome simultaneously. In a further embodiment, the present invention encompasses site-specific genome editing. The present invention is advantageous over the use of natural or artificial site-specific nucleases or recombinases, because it can introduce site-specific double-strand breaks to promote homologous recombination in the targeted genomic locus. In another embodiment, the present invention encompasses DNA sequence-specific interference. The present invention can be used to inactivate the genome of harmful DNA-based organisms, such as microorganisms, viruses, or even cancerous cells, by directly introducing breaks at specific sites in the genome of these organisms. The present invention provides methods and compositions for multiplexed genome engineering, because the CRISPR-Cas system of the present invention can be easily targeted to multiple sites in a genome through the use of multiple sequence-specific CRISPR spacer elements or guide sequences.

[0025] Therefore, it is not the object of the present invention to include any previously known products, methods of making the products, or methods of using the products, and therefore, the applicants reserve the right to do so and hereby disclose a disclaimer of any previously known products, methods of making the products, or methods of using the products.It is further noted that the present invention does not include within its scope any products, methods, or methods of making the products or methods of using the products that do not meet the description and enablement requirements of the USPTO (35 U.S.C. § 112, first paragraph) or the EPO (European Patent Convention, Article 83), and therefore, the applicants reserve the right to do so and hereby disclose a disclaimer of any previously described products, methods of making the products, or methods of using the products.

[0026] In this disclosure, and particularly in the claims and / or paragraphs, terms such as "comprises," "comprised," "comprising," and the like, may have the meaning ascribed to them in U.S. Patent Law; for example, they may mean "includes," "included," "including," and the like; terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. Patent Law, for example, it is noted that they permit elements not expressly recited, but exclude elements found in the prior art or that affect a basic or novel characteristic of the invention. These and other embodiments are disclosed or apparent from the following detailed description and are encompassed thereby.

[0027] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings. [Brief description of the drawings]

[0028] [Figure 1] A schematic model of the CRISPR system is shown. The Cas9 nuclease from Streptococcus pyogenes (yellow) is targeted to genomic DNA by a synthetic guide RNA (sgRNA) consisting of a 20 nt guide sequence (blue) and a scaffold (red). The guide sequence base pairs with the DNA target (blue) immediately upstream of a required 5'-NGG protospacer adjacent motif (PAM; magenta), and Cas9 mediates a double-stranded break (DSB) (red triangle) approximately 3 bp upstream of the PAM. [Figure 2A]Shown are exemplary CRISPR systems, possible mechanisms of action, exemplary adaptations for expression in eukaryotic cells, and results of tests evaluating nuclear localization and CRISPR activity. Figure 2C discloses SEQ ID NOs: 23-24, respectively, in order of appearance. Figure 2E discloses SEQ ID NOs: 25-27, respectively, in order of appearance. Figure 2F discloses SEQ ID NOs: 28-32, respectively, in order of appearance. [Figure 2B] Shown are exemplary CRISPR systems, possible mechanisms of action, exemplary adaptations for expression in eukaryotic cells, and results of tests evaluating nuclear localization and CRISPR activity. Figure 2C discloses SEQ ID NOs: 23-24, respectively, in order of appearance. Figure 2E discloses SEQ ID NOs: 25-27, respectively, in order of appearance. Figure 2F discloses SEQ ID NOs: 28-32, respectively, in order of appearance. [Figure 2C] Shown are exemplary CRISPR systems, possible mechanisms of action, exemplary adaptations for expression in eukaryotic cells, and results of tests evaluating nuclear localization and CRISPR activity. Figure 2C discloses SEQ ID NOs: 23-24, respectively, in order of appearance. Figure 2E discloses SEQ ID NOs: 25-27, respectively, in order of appearance. Figure 2F discloses SEQ ID NOs: 28-32, respectively, in order of appearance. [Figure 2D] Shown are exemplary CRISPR systems, possible mechanisms of action, exemplary adaptations for expression in eukaryotic cells, and results of tests evaluating nuclear localization and CRISPR activity. Figure 2C discloses SEQ ID NOs: 23-24, respectively, in order of appearance. Figure 2E discloses SEQ ID NOs: 25-27, respectively, in order of appearance. Figure 2F discloses SEQ ID NOs: 28-32, respectively, in order of appearance. [Figure 2E] Shown are exemplary CRISPR systems, possible mechanisms of action, exemplary adaptations for expression in eukaryotic cells, and results of tests evaluating nuclear localization and CRISPR activity. Figure 2C discloses SEQ ID NOs: 23-24, respectively, in order of appearance. Figure 2E discloses SEQ ID NOs: 25-27, respectively, in order of appearance. Figure 2F discloses SEQ ID NOs: 28-32, respectively, in order of appearance. [Figure 2F]Shown are exemplary CRISPR systems, possible mechanisms of action, exemplary adaptations for expression in eukaryotic cells, and results of tests evaluating nuclear localization and CRISPR activity. Figure 2C discloses SEQ ID NOs: 23-24, respectively, in order of appearance. Figure 2E discloses SEQ ID NOs: 25-27, respectively, in order of appearance. Figure 2F discloses SEQ ID NOs: 28-32, respectively, in order of appearance. [Figure 3A] The results of the evaluation of SpCas9 specificity for exemplary targets are shown in Figure 3A, which discloses SEQ ID NOs: 33, 26, and 34-44, respectively, in order of appearance. Figure 3C discloses SEQ ID NO: 33. [Figure 3B] The results of the evaluation of SpCas9 specificity for exemplary targets are shown in Figure 3A, which discloses SEQ ID NOs: 33, 26, and 34-44, respectively, in order of appearance. Figure 3C discloses SEQ ID NO: 33. [Figure 3C] The results of the evaluation of SpCas9 specificity for exemplary targets are shown in Figure 3A, which discloses SEQ ID NOs: 33, 26, and 34-44, respectively, in order of appearance. Figure 3C discloses SEQ ID NO: 33. [Figure 3D] The results of the evaluation of SpCas9 specificity for exemplary targets are shown in Figure 3A, which discloses SEQ ID NOs: 33, 26, and 34-44, respectively, in order of appearance. Figure 3C discloses SEQ ID NO: 33. [Figure 4A] Exemplary vector systems and results for their use in directing homologous recombination in eukaryotic cells are shown. Figure 4E discloses SEQ ID NO: 45. Figure 4F discloses SEQ ID NOs: 46-47, respectively, in order of appearance. Figure 4G discloses SEQ ID NOs: 48-52, respectively, in order of appearance. [Figure 4B] Exemplary vector systems and results for their use in directing homologous recombination in eukaryotic cells are shown. Figure 4E discloses SEQ ID NO: 45. Figure 4F discloses SEQ ID NOs: 46-47, respectively, in order of appearance. Figure 4G discloses SEQ ID NOs: 48-52, respectively, in order of appearance. [Figure 4C]Exemplary vector systems and results for their use in directing homologous recombination in eukaryotic cells are shown. Figure 4E discloses SEQ ID NO: 45. Figure 4F discloses SEQ ID NOs: 46-47, respectively, in order of appearance. Figure 4G discloses SEQ ID NOs: 48-52, respectively, in order of appearance. [Figure 4D] Exemplary vector systems and results for their use in directing homologous recombination in eukaryotic cells are shown. Figure 4E discloses SEQ ID NO: 45. Figure 4F discloses SEQ ID NOs: 46-47, respectively, in order of appearance. Figure 4G discloses SEQ ID NOs: 48-52, respectively, in order of appearance. [Figure 4E] Exemplary vector systems and results for their use in directing homologous recombination in eukaryotic cells are shown. Figure 4E discloses SEQ ID NO: 45. Figure 4F discloses SEQ ID NOs: 46-47, respectively, in order of appearance. Figure 4G discloses SEQ ID NOs: 48-52, respectively, in order of appearance. [Figure 4F] Exemplary vector systems and results for their use in directing homologous recombination in eukaryotic cells are shown. Figure 4E discloses SEQ ID NO: 45. Figure 4F discloses SEQ ID NOs: 46-47, respectively, in order of appearance. Figure 4G discloses SEQ ID NOs: 48-52, respectively, in order of appearance. [Figure 4G] Exemplary vector systems and results for their use in directing homologous recombination in eukaryotic cells are shown. Figure 4E discloses SEQ ID NO: 45. Figure 4F discloses SEQ ID NOs: 46-47, respectively, in order of appearance. Figure 4G discloses SEQ ID NOs: 48-52, respectively, in order of appearance. [Diagram 5]Tables of protospacer sequences (SEQ ID NOs: 16, 15, 14, 53-58, 18, 17, and 59-63, respectively, in order of appearance) are provided, along with the corresponding PAMs, summarizing modification efficiency results for exemplary S. pyogenes and S. thermophilus CRISPR system-based designed protospacer targets for loci in the human and mouse genomes. Cells were transfected with Cas9 and either pre-crRNA / tracrRNA or chimeric RNA and analyzed 72 hours after transfection. Percent indels were calculated based on Surveyor assay results from the indicated cell lines (N=3 for all protospacer targets, errors are standard error, ND indicates not detectable using the Surveyor assay, NT indicates not tested in this study). [Figure 6A] FIG. 6A shows a comparison of different tracrRNA transcripts for Cas9-mediated gene targeting. FIG. 6A discloses SEQ ID NOs: 64-65, respectively, in order of appearance. [Figure 6B] FIG. 6A shows a comparison of different tracrRNA transcripts for Cas9-mediated gene targeting. FIG. 6A discloses SEQ ID NOs: 64-65, respectively, in order of appearance. [Figure 6C] FIG. 6A shows a comparison of different tracrRNA transcripts for Cas9-mediated gene targeting. FIG. 6A discloses SEQ ID NOs: 64-65, respectively, in order of appearance. [Figure 7] FIG. 2 shows a schematic diagram of the surveyor nuclease assay for detection of double-strand break-induced microinsertions and deletions. [Figure 8] Figure 8 shows an exemplary bicistronic expression vector for the expression of CRISPR system elements in eukaryotic cells. Figure 8A discloses SEQ ID NOs: 66-68, respectively, in order of appearance. Figure 8B discloses SEQ ID NOs: 69-71, respectively, in order of appearance. [Figure 9]A histogram of the distance between the adjacent S. pyogenes SF370 locus 1 PAM (NGG) (Figure 9A) and the S. thermophilus LMD9 locus 2 PAM (NNAGAAW) (Figure 9B) in the human genome; and the distance for each PAM per chromosome (Chr) (Figure 9C). [Figure 10A] Figure 10 shows an exemplary CRISPR system, exemplary adaptation for expression in eukaryotic cells, and the results of a test evaluating CRISPR activity. Figure 10B discloses SEQ ID NO: 72-73, respectively, in order of appearance. Figure 10C discloses SEQ ID NO: 74. [Figure 10B] Figure 10 shows an exemplary CRISPR system, exemplary adaptation for expression in eukaryotic cells, and the results of a test evaluating CRISPR activity. Figure 10B discloses SEQ ID NO: 72-73, respectively, in order of appearance. Figure 10C discloses SEQ ID NO: 74. [Figure 10C] Figure 10 shows an exemplary CRISPR system, exemplary adaptation for expression in eukaryotic cells, and the results of a test evaluating CRISPR activity. Figure 10B discloses SEQ ID NO: 72-73, respectively, in order of appearance. Figure 10C discloses SEQ ID NO: 74. [Figure 10D] Figure 10 shows an exemplary CRISPR system, exemplary adaptation for expression in eukaryotic cells, and the results of a test evaluating CRISPR activity. Figure 10B discloses SEQ ID NO: 72-73, respectively, in order of appearance. Figure 10C discloses SEQ ID NO: 74. [Figure 11] FIG. 11 shows an exemplary operation of the CRISPR system for targeting genomic loci in mammalian cells. FIG. 11A discloses SEQ ID NO: 75. FIG. 11B discloses SEQ ID NOs: 76-78, respectively, in order of appearance. [Figure 12] Figure 12A shows the results of Northern blot analysis of crRNA processing in mammalian cells. [Figure 13] Exemplary selection of protospacers in human PVALB and mouse Th locus are shown. Figure 13A discloses SEQ ID NO: 80. Figure 13B discloses SEQ ID NO: 81. [Figure 14]FIG. 14 shows an exemplary protospacer and corresponding PAM sequence target of the S. thermophilus CRISPR system in the human EMX1 locus. FIG. 14 discloses SEQ ID NO:74. [Figure 15] A table of sequences (SEQ ID NOs: 82-93, respectively, in order of appearance) for the primers and probes used in the Surveyor, RFLP, genomic sequencing, and Northern blot assays is provided. [Figure 16A] FIG. 16A shows an exemplary operation of the CRISPR system with chimeric RNA and the results of a SURVEYOR assay for system activity in eukaryotic cells. FIG. 16B discloses SEQ ID NO:94. [Figure 16B] FIG. 16A shows an exemplary operation of the CRISPR system with chimeric RNA and the results of a SURVEYOR assay for system activity in eukaryotic cells. FIG. 16B discloses SEQ ID NO:94. [Figure 16C] FIG. 16A shows an exemplary operation of the CRISPR system with chimeric RNA and the results of a SURVEYOR assay for system activity in eukaryotic cells. FIG. 16B discloses SEQ ID NO:94. [Figure 17] 1 shows a graphical representation of the results of a SURVEYOR assay for CRISPR system activity in eukaryotic cells. [Figure 18] FIG. 18 shows an exemplary visualization of some S. pyogenes Cas9 target sites in the human genome using the UCSC genome browser. FIG. 18 discloses SEQ ID NOs: 95-173, respectively, in order of appearance. [Figure 19A] A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 19B] A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 19C]A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 19D] A circular representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 20A] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 20B] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 20C] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 20D] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 20E] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 20F] A linear representation of a phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (approximately 1400 amino acids) and two groups of small Cas9s (approximately 1100 amino acids). [Figure 21A]Genome editing via homologous recombination. (a) Schematic of SpCas9 nickase with D10A mutation in RuvC I catalytic domain. (b) Schematic depicting homologous recombination (HR) at the human EMX1 locus using either sense or antisense single-stranded oligonucleotide as repair template. The upper red arrow indicates the sgRNA cleavage site; PCR primers for genotyping (Tables J and K) are shown as arrows in the right panel. Figure 21C discloses SEQ ID NOs: 174-176, 174, 177 and 176, respectively, in order of appearance. (c) Sequence of the region modified by HR. d, SURVEYOR assay for wild-type (wt) and nickase (D10A) SpCas9-mediated indels at the EMX1 target 1 locus (n=3). Arrows indicate the position of predicted fragment sizes. [Figure 21B] Genome editing via homologous recombination. (a) Schematic of SpCas9 nickase with D10A mutation in RuvC I catalytic domain. (b) Schematic depicting homologous recombination (HR) at the human EMX1 locus using either sense or antisense single-stranded oligonucleotide as repair template. The upper red arrow indicates the sgRNA cleavage site; PCR primers for genotyping (Tables J and K) are shown as arrows in the right panel. Figure 21C discloses SEQ ID NOs: 174-176, 174, 177 and 176, respectively, in order of appearance. (c) Sequence of the region modified by HR. d, SURVEYOR assay for wild-type (wt) and nickase (D10A) SpCas9-mediated indels at the EMX1 target 1 locus (n=3). Arrows indicate the position of predicted fragment sizes. [Figure 21C]Genome editing via homologous recombination. (a) Schematic of SpCas9 nickase with D10A mutation in RuvC I catalytic domain. (b) Schematic depicting homologous recombination (HR) at the human EMX1 locus using either sense or antisense single-stranded oligonucleotide as repair template. The upper red arrow indicates the sgRNA cleavage site; PCR primers for genotyping (Tables J and K) are shown as arrows in the right panel. Figure 21C discloses SEQ ID NOs: 174-176, 174, 177 and 176, respectively, in order of appearance. (c) Sequence of the region modified by HR. d, SURVEYOR assay for wild-type (wt) and nickase (D10A) SpCas9-mediated indels at the EMX1 target 1 locus (n=3). Arrows indicate the position of predicted fragment sizes. [Figure 21D] Genome editing via homologous recombination. (a) Schematic of SpCas9 nickase with D10A mutation in RuvC I catalytic domain. (b) Schematic depicting homologous recombination (HR) at the human EMX1 locus using either sense or antisense single-stranded oligonucleotide as repair template. The upper red arrow indicates the sgRNA cleavage site; PCR primers for genotyping (Tables J and K) are shown as arrows in the right panel. Figure 21C discloses SEQ ID NOs: 174-176, 174, 177 and 176, respectively, in order of appearance. (c) Sequence of the region modified by HR. d, SURVEYOR assay for wild-type (wt) and nickase (D10A) SpCas9-mediated indels at the EMX1 target 1 locus (n=3). Arrows indicate the position of predicted fragment sizes. [Figure 22A] Figure 22A shows a single vector design for SpCas9. Figure 22A discloses SEQ ID NOs: 178-180, respectively, in order of appearance. Figure 22B discloses SEQ ID NO: 181. [Figure 22B] Figure 22A shows a single vector design for SpCas9. Figure 22A discloses SEQ ID NOs: 178-180, respectively, in order of appearance. Figure 22B discloses SEQ ID NO: 181. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The drawings herein are for illustrative purposes only and are not necessarily drawn to scale.

[0030] The terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "oligonucleotide" are used interchangeably. They refer to polymeric forms of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or their analogs. Polynucleotides can have any three-dimensional structure and can perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locuses) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotides can contain one or more modified nucleotides, such as methylated nucleotides or nucleotide analogs. Modifications to the nucleotide structure, if present, can be imparted before or after assembly of the polymer. The sequence of nucleotides can be interrupted by non-nucleotide components. A polynucleotide can be further modified after polymerization, such as by conjugation with a labeling component.

[0031] In the context of the present invention, the terms "chimeric RNA", "chimeric guide RNA", "guide R The terms "guide sequence", "single guide RNA" and "synthetic guide RNA" are used interchangeably and refer to a polynucleotide sequence that includes a guide sequence, a tracr sequence and a tracr mate sequence. The term "guide sequence" refers to an approximately 20 bp sequence within a guide RNA that defines a target site and can be used interchangeably with the terms "guide" or "spacer". The term "tracr mate sequence" can also be used interchangeably with the term "direct repeat". An exemplary CRISPR-Cas system is shown in FIG. 1.

[0032] The term "wild-type" as used herein is a term of the art understood by those of skill in the art and means the typical form of an organism, strain, gene or characteristic as it occurs in nature, as distinguished from mutant or variant forms.

[0033] The term "variant" as used herein should be taken to mean exhibiting a quality having a pattern that deviates from that occurring in nature.

[0034] The terms "non-naturally occurring" or "engineered" are used interchangeably and refer to the involvement of man. The terms, when referring to a nucleic acid molecule or polypeptide, mean that the nucleic acid molecule or polypeptide is at least substantially free from at least one other component with which they are naturally associated or found in the natural state.

[0035] "Complementarity" refers to the ability of a nucleic acid to form hydrogen bonds with another nucleic acid sequence, either by classical Watson-Crick or other non-classical types. Complementarity percentage indicates the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Fully complementary" means that all consecutive residues of a nucleic acid sequence will hydrogen bond with the same number of consecutive residues in a second nucleic acid sequence. As used herein, "substantially complementary" refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.

[0036] As used herein, "stringent conditions" for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence will predominantly hybridize to the target sequence and will not substantially hybridize to non-target sequences. Stringent conditions are generally sequence-dependent and vary depending on a number of factors. In general, the longer the sequence, the higher the temperature at which the sequence will specifically hybridize to its target sequence. Non-limiting examples of stringent conditions are detailed in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part I, Second Chapter "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, NY.

[0037] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized through hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogsteen binding, or in any other sequence-specific manner. The complex may include two strands forming a double-stranded structure, three or more strands forming a multistranded complex, a single self-hybridizing strand, or any combination thereof. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of PCR or the cleavage of a polynucleotide by an enzyme. A sequence that can hybridize to a given sequence is referred to as the "complement" of the given sequence.

[0038] As used herein, "expression" refers to the process by which a polynucleotide is transcribed from a DNA template (e.g., into an mRNA or other RNA transcript) and / or the transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein. The transcript and the encoded polypeptide can be collectively referred to as a "gene product." If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell.

[0039] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also encompasses amino acid polymers that have been modified, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. The term "amino acid" as used herein includes natural and / or unnatural or synthetic amino acids, including glycine and both D or L optical isomers, as well as amino acid analogs and peptidomimetics.

[0040] The terms "subject," "individual," and "patient" are used interchangeably herein to refer to a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets. Also included are tissues, cells, and their progeny of biological entities obtained in vivo or cultured in vitro.

[0041] The terms "therapeutic agent", "therapeutic agent" or "treatment agent" are used interchangeably and refer to a molecule or compound that confers some beneficial effect upon administration to a subject. Beneficial effects include enabling a diagnostic measurement; ameliorating a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder, or pathological condition; and generally neutralizing a disease, symptom, disorder, or pathological condition.

[0042] As used herein, "treatment" or "treat" or "alleviate" or "improve" are used interchangeably. These terms refer to an approach to obtain a benefit or desired result, for example, but not limited to, therapeutic benefit and / or preventive benefit. Therapeutic benefit refers to any treatment-related improvement or effect on one or more diseases, conditions, or symptoms being treated. For preventive benefit, the composition can be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more physiological symptoms of a disease, even if the disease, condition, or symptom has not yet been manifested.

[0043] The term "effective amount" or "therapeutically effective amount" refers to an amount of an agent sufficient to produce a benefit or desired result. The therapeutically effective amount may vary depending on one or more of the subject and condition being treated, the subject's weight and age, the severity of the condition, the mode of administration, etc., which can be easily determined by those skilled in the art. This term also applies to a dose that provides an image for detection by any one of the imaging methods described herein. The prescribed dose may vary depending on one or more of the specific agent selected, the administration regimen to be followed, whether it is administered in combination with other compounds, the timing of administration, the tissue to be imaged, and the physical delivery system in which it is carried.

[0044] The practice of the present invention employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics, and recombinant DNA, which are within the skill of one of ordinary skill in the art. See Sambrook, Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FMA Usubel, et al. eds., (1987)); Series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (MJ MacPherson, BD Hames and GR Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (RI Freshney, ed. (1987)).

[0045] Some aspects of the present invention relate to vector systems, including one or more vectors, or to the vector itself. Vectors can be designed for the expression of CRISPR transcripts (e.g., nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells. For example, CRISPR transcripts can be expressed in bacterial cells, such as Escherichia coli, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are further discussed in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, recombinant expression vectors can be transcribed and translated in vitro, for example, using T7 promoter regulatory sequences and T7 polymerase.

[0046] Vectors can be introduced into and propagated in prokaryotic cells. In some embodiments, prokaryotes are used to amplify copies of vectors to be introduced into eukaryotic cells or to be used as intermediate vectors in the production of vectors to be introduced into eukaryotic cells (e.g., amplifying plasmids as part of a viral vector packaging system). In some embodiments, prokaryotes are used to amplify copies of vectors to express one or more nucleic acids, e.g., to provide a source of one or more proteins for delivery to a host cell or host organism. Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to the protein encoded therein, e.g., to the amino terminus of the recombinant protein. Such fusion vectors can serve one or more purposes, e.g., (i) increase expression of recombinant proteins; (ii) increase solubility of recombinant proteins; and (iii) aid in the purification of recombinant proteins by acting as a ligand in affinity purification. In fusion expression vectors, a proteolytic cleavage site is often introduced at the junction of the fusion moiety and the recombinant protein to allow the separation of the recombinant protein from the fusion moiety after purification of the fusion protein. Such enzymes and their cognate recognition sequences include factor Xa, thrombin and enterokinase. Exemplary fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, NJ), which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A to the target recombinant protein, respectively.

[0047] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

[0048] In some embodiments, the vector is a yeast expression vector.Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec1 (Baldari, et al., 1987.EMBO J.6:229-234), pMFa (Kuijan and Herskowitz, 1982.Cell 30:933-943), pJRY88 (Schultz et al., 1987.Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.) and picZ (InVitrogen Corp, San Diego, Calif.).

[0049] In some embodiments, the vector uses a baculovirus expression vector to drive protein expression in insect cells. Baculovirus vectors available for protein expression in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3:2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170:31-39).

[0050] In some embodiments, the vector may drive the expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329:840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6:187-195). When used in mammalian cells, expression vector control functions are typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus type 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, see, for example, Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

[0051] In some embodiments, the recombinant mammalian expression vector can direct expression of the nucleic acid preferentially in a particular cell type (e.g., expressing the nucleic acid using tissue-specific regulatory elements). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8:729-733) and immunoglobulins (Baneiji, et al., 1983. Cell 33:729-740; Queen and Baltimore, 1983. Cell 33:741-748), neuronal cell-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreatic-specific promoters (Edlund, et al., 1985. Science 230:912-916), and mammary gland-specific promoters (e.g., whey promoter; U.S. Pat. No. 4,873,316 and European Patent Publication No. 264,166). Developmentally regulated promoters, such as murine hox promoters (Kessel and Gruss, 1990. Science 249:374-379) and the alpha-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3:537-546), are also encompassed.

[0052] In some embodiments, the regulatory element is operably linked to one or more elements of the CRISPR system to drive the expression of one or more elements of the CRISPR system.Generally, CRISPR (Clustered Regularly Interspaced Short Repeats), also known as SPIDR (Spacer Interspersed Direct Repeat), constitutes a family of DNA loci that are usually specific to certain bacterial species.CRISPR loci include a distinct class of interspersed short sequence repeats (SSRs) recognized in Escherichia coli (E. coli) (Ishino et al., J. Bacteriol., 169:5429-5433

[1987] ; and Nakata et al., J. Bacteriol., 171:3553-3556

[1989] ) and related genes. Similar interspersed SSRs have been identified in Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (see Groenen et al., Mol. Microbiol., 10:1057-1065

[1993] ; Hoe et al., Emerg. Infect. Dis., 5:254-263

[1999] ; Masepohl et al., Biochim. Biophys. Acta 1307:26-30

[1996] ; and Mojica et al., Mol. Microbiol., 17:85-93

[1995] ). CRISPR loci typically differ from other SSRs in the structure of their repeats, which are termed short regularly interspaced repeats (SRSRs) (Janssen et al., OMICS J. Integ. Biol., 6:23-33

[2002] ; and Mojica et al., Mol. Microbiol., 36:244-246

[2000] ). In general, the repeats are short elements that occur in clusters that are regularly spaced by unique intervening sequences of substantially constant length (Mojica et al.,

[2000] , supra). The repeat sequences are highly conserved between strains, butThe number of interspersed repeats and the sequence of the spacer region typically vary from strain to strain (van Embden et al., J. Bacteriol., 182:2393-2401

[2000] ). CRISPR loci have been identified in over 40 prokaryotes (e.g., Jansen et al., Mol. Microbiol., 43:1565-1575

[2002] ; and Mojica et al. See, e.g., et al., 2005), examples of genera include, but are not limited to, Aeropyrum, Pyrobaculum, Sulfolobus, Archaeoglobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophilus, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, and the like. fex, Porphyromonas, Chlorobium, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium, Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desulfovibrio, Geobacter, Myxococcus, Campylobacter,The genera Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methylococcus, Pasteurella, Photobacterium, Salmonella, Xanthomonas, Yersinia, Treponema, and Thermotoga.

[0053] In general, "CRISPR system" refers collectively to transcripts and other elements involved in directing the expression or activity of CRISPR-associated ("Cas") genes, such as sequences encoding Cas genes, tracr (transactivating CRISPR) sequences (e.g., tracrRNA or active partial tracrRNA), tracr mate sequences (including "direct repeats" and partial direct repeats processed by tracrRNA in the context of endogenous CRISPR systems), guide sequences (also referred to as "spacers" in the context of endogenous CRISPR systems), or other sequences and transcripts from a CRISPR locus. In some embodiments, one or more elements of the CRISPR system are derived from a type I, type II, or type III CRISPR system. In some embodiments, one or more elements of the CRISPR system are derived from a particular organism that contains an endogenous CRISPR system, such as Streptococcus pyogenes. In general, CRISPR systems are characterized by elements that promote the formation of CRISPR complexes in target sequences (also referred to as protospacers for endogenous CRISPR systems). In the context of CRISPR complex formation, "target sequence" refers to a sequence that guide sequences are designed to have complementarity with, and hybridization between target sequence and guide sequence promotes the formation of CRISPR complexes. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization and promote the formation of CRISPR complexes. Target sequences can include any polynucleotide, for example, DNA or RNA polynucleotides. In some embodiments, target sequences are located in the nucleus or cytoplasm of a cell. In some embodiments, target sequences can be present in organelles of eukaryotic cells, for example, mitochondria or chloroplasts. A sequence or template that can be used for recombination into a targeted locus that includes a target sequence is referred to as "editing template" or "editing polynucleotide" or "editing sequence". In an aspect of the present invention, an exogenous template polynucleotide can be referred to as an editing template. In one aspect of the invention, the recombination is homologous recombination.

[0054] Typically, for endogenous CRISPR systems, the formation of a CRISPR complex (including a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage of one or both strands in or near the target sequence (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs therefrom). Without being bound by theory, the tracr sequence may comprise or consist of all or a portion of the wild-type tracr sequence (e.g., more than about or about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of the wild-type tracr sequence), and may also form part of a CRISPR complex, for example, by hybridization along at least a portion of the tracr sequence with all or a portion of the tracr mate sequence operably linked to the guide sequence. In some embodiments, the tracr sequence has sufficient complementarity to the tracr mate sequence to hybridize and participate in the formation of a CRISPR complex. As with the target sequence, full complementarity is not required, provided that there is sufficient complementarity to be functional. In some embodiments, the tracr sequence has at least 50%, 60%, 70%, 80%, 90%, 95% or 99% sequence complementarity along the length of the tracr mate sequence when optimally aligned. In some embodiments, one or more vectors that drive the expression of one or more elements of the CRISPR system are introduced into the host cell, such that the expression of the elements of the CRISPR system directs the formation of a CRISPR complex at one or more target sites. For example, the Cas enzyme, the guide sequence that is linked to the tracr mate sequence, and the tracr sequence can each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more of the elements expressed from the same or different regulatory elements can be combined in a single vector, and one or more additional vectors that provide any components of the CRISPR system are not included in the first vector.The CRISPR system elements combined in a single vector can be arranged in any suitable orientation, for example, an element can be located 5' (upstream) or 3' (downstream) relative to a second element. The coding sequence of an element can be located on the same or opposite strand of the coding sequence of a second element and oriented in the same or opposite orientation. In some embodiments, a single promoter drives the expression of a transcript encoding a CRISPR enzyme and one or more of a guide sequence, a tracr mate sequence (optionally operably linked to a guide sequence), and a tracr sequence (e.g., each in a different intron, two or more in at least one intron, or all in a single intron) embedded within one or more intron sequences. In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter. A single vector construct of SpCas9 is shown in FIG. 22.

[0055] In some embodiments, the vector comprises one or more insertion sites, such as restriction endonuclease recognition sequences (also referred to as "cloning sites"). In some embodiments, one or more insertion sites (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and / or downstream of one or more sequence elements of one or more vectors. In some embodiments, the vector comprises an insertion site upstream of the tracr mate sequence and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that the guide sequence directs sequence-specific binding of the CRISPR complex to a target sequence in a eukaryotic cell after insertion of the guide sequence into the insertion site and upon expression. In some embodiments, the vector comprises two or more insertion sites, each of which is located between two tracr mate sequences to allow insertion of the guide sequence at the respective site. In such an arrangement, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or a combination thereof. When using multiple different guide sequences, a single expression construct can be used to target CRISPR activity to multiple different corresponding target sequences in cells.For example, a single vector can contain about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more guide sequences.In some embodiments, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of such guide sequence-containing vectors can be provided and optionally delivered to cells.

[0056] In some embodiments, the vector comprises a regulatory element operably linked to an enzyme coding sequence that encodes a CRISPR enzyme, e.g., a Cas protein. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. These enzymes are known; for example, the amino acid sequence of S.pyogenes Cas9 protein can be found in SwissProt database under accession number Q99ZW2. In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, for example, Cas9. In some embodiments, the CRISPR enzyme is Cas9, and can be Cas9 from S.pyogenes or S.pneumoniae. In some embodiments, the CRISPR enzyme directs the cleavage of one or both strands at the location of the target sequence, for example, within the target sequence and / or the complementary strand of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500 or more base pairs from the first or last nucleotide of the target sequence. In some embodiments, the vector encodes a CRISPR enzyme that is mutated relative to the corresponding wild-type enzyme, such that the mutant CRISPR enzyme lacks the ability to cleave one or both strands of the target polynucleotide containing the target sequence.For example, an aspartic acid to alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that turn Cas9 into a nickase include, but are not limited to, H840A, N854A, and N863A. In an embodiment of the present invention, the nickase can be used for genome editing via homologous recombination. For example, FIG. 21 shows genome editing via homologous recombination. FIG. 21(a) shows a schematic diagram of SpCas9 nickase with a D10A mutation in the RuvCI catalytic domain. (b) Schematic diagram showing homologous recombination (HR) at the human EMX1 locus using either a sense or antisense single-stranded oligonucleotide as a repair template. (c) Sequence of the region modified by HR. d, SURVEYOR assay for wild-type (wt) and nickase (D10A) SpCas9-mediated indels at the EMX1 target 1 locus (n=3). Arrows indicate the position of predicted fragment sizes.

[0057] In some embodiments, Cas9 nickase can be used in combination with a guide sequence, for example, two guide sequences that target the sense and antisense strands of a DNA target, respectively. This combination allows both strands to be nicked and used to induce NHEJ. Applicants have demonstrated the efficacy of two nickase targets (i.e., sgRNAs targeted to different strands of DNA at the same localization) in inducing mutagenic NHEJ (data not shown). Although single nickase (Cas9-D10A with a single sgRNA) cannot induce NHEJ and create indels, applicants have shown that double nickase (Cas9-D10A and two sgRNAs targeted to different strands at the same localization) can do so in human embryonic stem cells (hESCs). The efficiency is about 50% of nuclease (i.e., normal Cas9 without D10 mutation) in hESCs.

[0058] As a further example, two or more catalytic domains (RuvC I, RuvC II, and RuvC III) of Cas9 can be mutated to produce a mutant Cas9 that is substantially devoid of all DNA cleavage activity. In some embodiments, the D10A mutation is combined with one or more of the H840A, N854A, or N863A mutations to produce a Cas9 enzyme that is substantially devoid of all DNA cleavage activity. In some embodiments, a CRISPR enzyme is considered to be substantially devoid of all DNA cleavage activity if the DNA cleavage activity of the mutant enzyme is less than about 25%, 10%, 5%, 1%, 0.1%, 0.01%, or less than its non-mutated form. Other mutations may be useful; if the Cas9 or other CRISPR enzyme is from a species other than S. pyogenes, corresponding amino acid mutations can be made to achieve a similar effect.

[0059] In some embodiments, the enzyme coding sequence encoding the CRISPR enzyme is codon-optimized for expression in a particular cell, for example, a eukaryotic cell.The eukaryotic cell may be or be derived from a particular organism, for example, a mammal, for example, but not limited to, a human, a mouse, a rat, a rabbit, a dog, or a non-human primate.In general, codon optimization refers to the process of modifying a nucleic acid sequence for improved expression in a target host cell by replacing at least one codon (for example, about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of a natural sequence with a more frequent or most frequent codon used in the gene of the host cell, while maintaining the natural amino acid sequence.Different species show a particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of messenger RNA (mRNA) translation, which in turn appears to depend, among other things, on the properties of the codons being translated and on the availability of specific transfer RNA (tRNA) molecules. The dominance of tRNAs selected in a cell is generally a reflection of the codons most frequently used in peptide synthesis. Thus, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example in "codon usage databases," and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon-optimizing a particular sequence for expression in a particular host cell are also available, for example, Gene Forge (Aptagen; Jacobus, PA).In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all of the codons) in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.

[0060] In general, a guide sequence is any polynucleotide sequence that has sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is greater than about or about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more when optimally aligned using a suitable alignment algorithm. Optimal alignment can be determined using any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, CA), and the like. Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, the guide sequence is about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the guide sequence is about 75, 50, 45, 40, 35, 30, 25, 36, 37, 38, 39, 40, 45, 50, 75, or more nucleotides in length. The length of the guide sequence is less than 1, 20, 15, 12 or less nucleotides.The ability of the guide sequence to direct the sequence-specific binding of CRISPR complex to target sequence can be evaluated by any suitable assay.For example, the components of CRISPR system sufficient to form CRISPR complex, for example, the guide sequence to be tested, can be provided to the host cell having the corresponding target sequence, for example, by transfection with the vector encoding the components of CRISPR sequence, and then the preferential cleavage in the target sequence is evaluated, for example, by Surveyor assay as described herein.Similarly, cleavage of a target polynucleotide sequence can be assessed in a test tube by providing the target sequence, a component of a CRISPR complex, such as a control guide sequence that is different from the guide sequence to be tested and the test guide sequence, and comparing the rate of binding or cleavage at the target sequence between the test and control guide sequence reactions. Other assays are contemplated and will be recognized by those of skill in the art.

[0061] Guide sequences can be selected to target any target sequence. In some embodiments, the target sequence is a sequence in the genome of a cell. Exemplary target sequences include those that are unique in the target genome. For example, for S. pyogenes Cas9, a unique target sequence in the genome can include a Cas9 target site of the form MMMMMMMNNNNNNNNNNNNNXGG, where NNNNNNNNNNNNXGG (N is A, G, T, or C; X can be anything) has a single occurrence in the genome. A unique target sequence in the genome can include a S. pyogenes Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXGG, where NNNNNNNNNNNXGG (N is A, G, T, or C; X can be anything) has a single occurrence in the genome. For S. thermophilus CRISPR1Cas9, a unique target sequence in the genome can include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXXAGAAW (SEQ ID NO:1), which has a single occurrence in the genome, NNNNNNNNNNNNXXAGAAW (SEQ ID NO:2) (N is A, G, T, or C; X can be anything; W is A or T). A unique target sequence in the genome can include a S. thermophilus CRISPR1Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXXAGAAW (SEQ ID NO:3), which has a single occurrence in the genome, NNNNNNNNNNNXXAGAAW (SEQ ID NO:4) (N is A, G, T, or C; X can be anything; W is A or T). For S. pyogenes Cas9, a unique target sequence in the genome can include a Cas9 target site of the form MMMMMMMNNNNNNNNNNNNNXGGXG, where NNNNNNNNNNNNXGGXG (N is A, G, T, or C; X can be anything) has a single occurrence in the genome.A unique target sequence in a genome can include a S. pyogenes Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXGGXG, where NNNNNNNNNNNXGGXG (N is A, G, T, or C; X can be anything) has a single occurrence in the genome. In each of these sequences, "M" can be A, G, T, or C and need not be considered in identifying the sequence as unique.

[0062] In some embodiments, the guide sequence is selected to reduce the degree of secondary structure in the guide sequence. The secondary structure can be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimum Gibbs free energy. An example of one such algorithm is mFold, described by Zuker and Stiegler (Nucleic Acids Res.9(1981),133-148). Another exemplary folding algorithm is the online web server RNAfold, developed by the Institute for Theoretical Chemistry at the University of Vienna, which uses a centroid structure prediction algorithm (see, for example, A. R. Gruber et al., 2008, Cell 106(1):23-24; and P. A. Carr and G. M. Church, 2009, Nature Biotechnology 27(12):1151-62). Further algorithms can be found in U.S. Provisional Patent Application No. 61 / 836,080 (Attorney Docket No. 44790.11.2022; Broad Reference No. BI-2013 / 004A), which is incorporated by reference herein.

[0063] In general, the tracr mate sequence includes any sequence that has sufficient complementarity with the tracr sequence to promote one or more of the following: (1) excision of the guide sequence flanked by the tracr mate sequence in cells that contain the corresponding tracr sequence; and (2) formation of a CRISPR complex in the target sequence, the CRISPR complex including the tracr mate sequence hybridized to the tracr sequence. In general, the degree of complementarity is based on the optimal alignment of the tracr mate sequence and the tracr sequence along the shorter length of the two sequences. The optimal alignment can be determined by any suitable alignment algorithm, and can further account for secondary structures, such as self-complementarity within the tracr sequence or the tracr mate sequence. In some embodiments, the degree of complementarity between the tracr sequence and the tracr mate sequence along the shorter length of the two sequences is greater than about or about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or more when optimally aligned. An exemplary illustration of optimal alignment between the tracr sequence and the tracr mate sequence is provided in Figures 10B and 11B. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides long. In some embodiments, the tracr sequence and the tract mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript with a secondary structure, e.g., a hairpin. The preferred loop-forming sequence used in the hairpin structure is 4 nucleotides long and most preferably has the sequence GAAA. However, longer or shorter loop sequences can be used, as can alternative sequences. The sequence preferably includes a nucleotide triplet (e.g., AAA) and an additional nucleotide (e.g., C or G). Examples of loop-forming sequences include CAAA and AAAG. In one embodiment of the invention, the transcript or transcribed polynucleotide sequence has at least two or more hairpins.In a preferred embodiment, the transcript has 2, 3, 4 or 5 hairpins. In another further embodiment of the present invention, the transcript has at most 5 hairpins. In some embodiments, the single transcript further comprises a transcription termination sequence; preferably, this is a poly-T sequence, e.g., 6 T nucleotides. An exemplary illustration of such a hairpin structure is provided in the lower portion of FIG. 11B, where the final "N" and the portion of the sequence 5' upstream of the loop correspond to the tracr mate sequence, and the portion of the sequence 3' upstream of the loop correspond to the tracr sequence. Further non-limiting examples of single polynucleotides comprising guide sequence, tracr mate sequence, and tracr sequence are as follows (listed from 5' to 3'), where "N" represents the bases of the guide sequence, the first block of lower case letters represents the tracr mate sequence, the second block of lower case letters represents the tracr sequence, and the final poly-T sequence represents the transcription terminator: [ka] In some embodiments, sequences (1) through (3) are used in combination with Cas9 from S. thermophilus CRISPR1. In some embodiments, sequences (4) through (6) are used in combination with Cas9 from S. pyogenes. In some embodiments, the tracr sequence is a separate transcript from the transcript containing the tracr mate sequence (e.g., as illustrated in the top diagram of FIG. 11B).

[0064] In some embodiments, CRISPR enzyme is part of a fusion protein that includes one or more heterologous protein domains (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more domains of CRISPR enzyme). CRISPR enzyme fusion protein can include any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that can be fused to CRISPR enzyme include, but are not limited to, epitope tags, reporter gene sequences, and protein domains that have one or more of the following activities: methylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity, and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tag, V5 tag, FLAG tag, influenza hemagglutinin (HA) tag, Myc tag, VSV-G tag, and thioredoxin (Trx) tag. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins, such as blue fluorescent protein (BFP). CRISPR enzymes can be fused to gene sequences encoding proteins or protein fragments that bind to DNA molecules or other cellular molecules, such as, but not limited to, maltose binding protein (MBP), S-tags, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in U.S. Patent Publication No. 20110059502, which is incorporated herein by reference. In some embodiments, a tagged CRISPR enzyme is used to identify the location of the target sequence.

[0065] In one aspect of the invention, reporter genes, including but not limited to glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins, such as blue fluorescent protein (BFP), can be introduced into cells to encode gene products that function as markers to measure altered or modified expression of the gene product. In a further embodiment of the invention, a DNA molecule encoding a gene product can be introduced into cells via a vector. In a preferred embodiment of the invention, the gene product is luciferase. In a further embodiment of the invention, the expression of the gene product is reduced.

[0066] In some aspects, the present invention provides a method comprising delivering one or more polynucleotides, such as, or one or more vectors described herein, one or more transcripts thereof, and / or one or more proteins transcribed therefrom, to a host cell. The present invention serves as a basic platform for enabling targeted modification of DNA-based genomes. This can be coordinated with many delivery systems, including but not limited to, viruses, liposomes, electroporation, microinjection and conjugation. In some aspects, the present invention further provides cells produced by such cells, and organisms (e.g., animals, plants, or fungi) that contain or are produced from such cells. In some embodiments, the CRISPR enzyme in combination with (and optionally complexed with) a guide sequence is delivered to the cell. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of the CRISPR system to cells in culture or into a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g., transcripts of the vectors described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, e.g., liposomes. Viral vector delivery systems include DNA and RNA viruses with episomal or integrated genomes after delivery to cells.For general overviews of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Felgner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51(1):31-44 (1995); Haddada et al., in Current Topics in Microbiology and See Immunology Doerfler and Boehm (eds) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).

[0067] Methods of non-viral delivery of nucleic acid include lipofection, nucleofection, microinjection, gene gun, virosome, liposome, immunoliposome, polycation or lipid:nucleic acid conjugate, naked DNA, artificial virion, and drug-enhanced DNA uptake.Lipofection is described, for example, in U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355, and lipofection reagents are commercially available (e.g., Transfectam™ and Lipofectin™).Cationic and neutral lipids suitable for efficient receptor-recognition lipofection of polynucleotides include those of Felgner, WO 91 / 17424; WO 91 / 16024.Delivery can be to cells (e.g., in vitro or ex vivo administration) or to target tissue (e.g., in vivo administration).

[0068] The preparation of lipid:nucleic acid complexes, including targeted liposomes, such as immunolipid complexes, is well known to those of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); see U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787.

[0069] The use of RNA or DNA virus-based systems for the delivery of nucleic acids takes advantage of the highly evolved process of targeting viruses to defined cells in the body and transporting the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, and optionally the modified cells can be administered to patients (ex vivo). Conventional virus-based systems can include retroviral, lentiviral, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome is considered for retroviral, lentiviral and adeno-associated virus gene transfer methods, often resulting in long-term expression of the inserted transgene. Furthermore, high transduction efficiency has been observed in many different cell types and target tissues.

[0070] The tropism of retroviruses can be altered by incorporating foreign envelope proteins to expand the potential target population of target cells. Lentiviral vectors are retroviral vectors that can transduce or infect non-dividing cells and typically produce high viral titers. Thus, the choice of retroviral gene transfer system depends on the target tissue. Retroviral vectors contain cis-acting long terminal repeats that have packaging capacity for foreign sequences up to 6-10 kb. The minimal cis-acting LTRs are sufficient for replication and packaging of the vector, which is then used to integrate a therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based on murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), or combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J. Virol. 66:1635-1640 (1992); Sommnerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); PCT / US94 / 05700). In applications where transient expression is preferred, adenovirus-based systems can be used. Adenovirus-based vectors can show extremely high transduction efficiency in many cell types and do not require cell division. High titers and expression levels have been obtained for such vectors. The vectors can be produced in large quantities in a relatively simple system.For example, adeno-associated virus ("AAV") vectors can also be used to transduce cells with target nucleic acids in the in vitro production of nucleic acids and peptides, as well as for in vivo and ex vivo gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93 / 24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994). The construction of recombinant AAV vectors has been described in numerous publications, e.g., U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 5:3251-3260 (1985); al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989).

[0071] Typically, packaging cells are used to form viral particles that can infect host cells. Such cells include 293 cells that package adenovirus, and ψ2 or PA317 cells that package retrovirus. Viral vectors used in gene therapy are usually produced by producing cell lines that package nucleic acid vectors into viral particles. The vector typically contains the minimum viral sequences required for packaging and subsequent integration into the host, with other viral sequences being replaced by an expression cassette for the polynucleotide to be expressed. Missing viral functions are typically provided in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only have ITR sequences from the AAV genome that are required for packaging and integration into the host genome. Viral DNA is packaged into a cell line that contains a helper plasmid that encodes other AAV genes, i.e., rep and cap, but lacks ITR sequences. The cell line can also be infected with adenovirus as a helper. Helper virus promotes the replication of AAV vector and the expression of AAV genes from helper plasmid.Helper plasmid is not packaged in significant amounts due to the lack of ITR sequence.Contamination by adenovirus can be reduced, for example, by heat treatment, to which adenovirus is more sensitive than AAV.Additional methods of delivering nucleic acid to cells are known to those skilled in the art.See, for example, US Patent Publication No. 20030087817, which is incorporated herein by reference.

[0072] In some embodiments, host cells are transfected with one or more vectors described herein, either transiently or non-transiently. In some embodiments, cells are transfected as they naturally occur in a subject. In some embodiments, the cells to be transfected are taken from a subject. In some embodiments, the cells are derived from cells, e.g., cell lines, taken from a subject. A wide range of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, HeLa-S3, Huh1, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Panc1, PC-3, TF1, CTLL-2, C1R, Rat6, CV1, RPTE, A10, T24, J82, A375, ARH-77, Calu1, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.01, LRMB, Bcl-1, BC-3, IC21, DLD2, Raw264.7, NRK, NRK-52E, MRC5, MEF, Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelium, BALB / 3T3 mouse embryonic fibroblasts, 3T3Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis , A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1 cells, BEAS-2B, bEnd.3, BHK-21, BR29 3, BxPC3, C3H-10T1 / 2, C6 / 36, Cal-27, CHO, CHO-7, CHO-IR, CHO-K1, CHO-K2, CHO-T, CHO Dhfr- / -, COR-L23, COR-L23 / CPR, COR-L23 / 5010, COR-L23 / R23, COS-7, COV-434, CML T1, CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6 / AR1, EMT6 / AR10.0, FM3, H1299, H69, HB54, HB55, HCA2, HEK-293, HeLa, Hepa1c1c7, HL-60, HMEC, HT-29, Jurkat, JY cells, K562 cells, Ku 812, KCL22, KG1, KYO1, LNCap, Ma-Mel1-48, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK II, MDCK II, MOR / 0.2R, MONO-MAC6, MTD-1A, MyEnd, NCI-H69 / CPR, NCI-H69 / LX10, NCI-H69 / LX20, NCI-H69 / LX4, NIH-3T3, NALM-1, NW-145, OPCN / OPCT cell lines, Peer, PNT-1A / PNT2, RenCa, RIN-5F, RMA / RMAS, Saos-2 cells, Sf-9, SkBr3, T2, T-47D, T84, THP1 cell lines, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-1, YAR, and transgenic variants thereof. Cell lines are available from a variety of sources known to those of skill in the art (see, e.g., American Type Culture Collection (ATCC), Manassus, Va.). In some embodiments, cells transfected with one or more vectors described herein are used to establish new cell lines that contain one or more vector-derived sequences. In some embodiments, cells that have been transiently transfected with components of a CRISPR system described herein (e.g., by transient transfection of one or more vectors or transfection with RNA) and modified through the activity of a CRISPR complex are used to establish new cell lines that include cells that contain modifications but lack any other exogenous sequences. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells, are used in the evaluation of one or more test compounds.

[0073] An embodiment of the present invention relates to the generation of isogenic lines of mammalian cells for the study of genetic variation of disease. A further embodiment of the present invention relates to the generation of genetically modified animal models, either transgenic or virally mediated delivery. The present invention also encompasses the genomic modification of microorganisms, cells, plants, animals or synthetic organisms for the production of biomedically, agriculturally and industrially useful products. In yet another embodiment, the present invention encompasses gene therapy. The present invention can be used as a biological research tool for understanding genomes, for example, gene knockout studies. The present invention relates to many other methods and compositions that rely on the fundamental ability to edit and rewrite the DNA content of genomes, as well as targeted inactivation of DNA-based organisms. The present invention can also be used as a therapeutic agent to target defined strains of bacterial infections, viral infections, and the like.

[0074] In some embodiments, one or more vectors described herein are used to produce non-human transgenic animals or transgenic plants. In some embodiments, the transgenic animal is a mammal, such as a mouse, rat, or rabbit. In some embodiments, the organism or subject is a plant. In some embodiments, the organism or subject or plant is an algae. Methods for producing transgenic plants and animals are known in the art and generally start from, for example, the methods of cell transfection described herein. Transgenic plants, particularly crops and algae, as well as transgenic animals are provided. Transgenic animals or plants may be useful in applications other than providing disease models. These may include, for example, food or feed production through the expression of higher protein, carbohydrate, nutrient or vitamin levels than normally found in wild type. In this regard, transgenic plants, particularly legumes and tubers, and animals, particularly mammals, such as livestock (cattle, sheep, goats and pigs), as well as poultry and edible insects are preferred.

[0075] Transgenic algae or other plants, such as canola, can be particularly useful, for example, in the production of vegetable oils or biofuels, such as alcohols (especially methanol and ethanol). They can be engineered to express or overexpress high levels of oils or alcohols for use in the oil or biofuel industry.

[0076] In one aspect, the present invention provides a method for modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo or in vitro. In some embodiments, the method comprises sampling a cell or a population of cells from a human or non-human animal or plant (including microalgae) and modifying one or more cells. Cultivation can be carried out ex vivo at any stage. One or more cells can also be reintroduced into a non-human animal or plant (including microalgae).

[0077] In one aspect, the present invention provides a method for modifying target polynucleotide in eukaryotic cell.In some embodiments, the method comprises: allowing CRISPR complex to bind to target polynucleotide to cause cleavage of said target polynucleotide, thereby modifying target polynucleotide, wherein CRISPR complex comprises CRISPR enzyme complexed with guide sequence that hybridizes to target sequence in said target polynucleotide, and said guide sequence is then bound to tracr mate sequence that hybridizes to tracr sequence.

[0078] In one aspect, the present invention provides a method for modifying the expression of polynucleotide in eukaryotic cells.In some embodiments, the method comprises: binding CRISPR complex to polynucleotide, and said binding results in increasing or decreasing the expression of said polynucleotide;CRISPR complex comprises CRISPR enzyme complexed with guide sequence that hybridizes to target sequence in said target polynucleotide, and said guide sequence is then bound to tracr mate sequence that hybridizes to tracr sequence.

[0079] With recent advances in crop genomics, the skill of using CRISPR-Cas system to perform efficient and cost-effective gene editing and manipulation allows for rapid selection and comparison of single and multiplexed genetic manipulations to transform such genomes for improved production and improved traits.In this regard, reference is made to the following US patents and publications: US Patent No. 6,603,061-Agrobacterium-Mediated Plant Transformation Method; US Patent No. 7,868,149-Plant Genome Sequences and Uses Thereof and US Patent Publication No. 2009 / 0100536-Transgenic Plants with Enhanced Agronomic Traits, the entire contents and disclosures of each of which are incorporated herein by reference in their entirety.In carrying out the present invention, the contents and disclosures of Morrell et al. "Crop genomics: advances and applications" Nat Rev Genet. 2011 Dec 29; 13(2): 85-96 are also incorporated herein by reference in their entirety.

[0080] In plants, pathogens are often host-specific. For example, Fusarium oxysporum f.sp.lycopersici, which causes tomato wilt, attacks only tomatoes, F.oxysporum f.dianthii, and Puccinia graminis f.sp.tritici, which attacks only wheat. Plants have pre-existing and inducible defenses to resist most pathogens. Mutation and recombination events throughout plant development result in genetic variations that cause susceptibility, especially when the pathogen reproduces more frequently than the plant. In plants, non-host resistance can exist, e.g., the host and the pathogen are incompatible. Horizontal resistance, e.g., partial resistance to all species of pathogens, typically controlled by many genes, and vertical resistance, e.g., complete resistance to some species of pathogens but not others, typically controlled by a few genes, can also exist. At the gene-by-gene level, plants and pathogens evolve together, with some genetic changes balanced by others. Thus, using natural variation, breeders combine the most useful genes for yield, quality, uniformity, cold hardiness, and resistance. Sources of resistance genes include natural or exotic species, landraces, wild plant relatives, and induced mutations, such as treating plant material with mutagenizing agents. Using the present invention, plant breeders are provided with new tools to induce mutations. Thus, those skilled in the art can analyze the genomes of sources of resistance genes and use the present invention in varieties with desired characteristics or traits to induce the emergence of resistance genes more precisely than traditional mutagenizing agents, thus accelerating and improving plant breeding programs.

[0081] In one aspect, the present invention provides a kit that contains any one or more of the elements disclosed in the above method and composition. In some embodiments, the kit includes a vector system and instructions for using the kit. In some embodiments, the vector system includes: (a) a first regulatory element that is operably linked to one or more insertion sites for inserting a tracr mate sequence and a guide sequence upstream of the tracr mate sequence (the guide sequence, when expressed, directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotic cell, the CRISPR complex comprising (1) a guide sequence that hybridizes to a target sequence, and (2) a CRISPR enzyme that is complexed with the tracr mate sequence that hybridizes to the tracr sequence); and / or (b) a second regulatory element that is operably linked to an enzyme coding sequence that encodes the CRISPR enzyme that comprises a nuclear localization sequence. The elements can be provided individually or in combination, and can be provided in any suitable container, for example, a vial, a bottle, or a tube. In some embodiments, the kit includes instructions in one or more languages, for example, in two or more languages.

[0082] In some embodiments, the kit includes one or more reagents used in a process utilizing one or more of the elements described herein. The reagents can be provided in any suitable container. For example, the kit can provide one or more reaction or storage buffers. The reagents can be provided in a form that can be used in a particular assay or in a form that requires the addition of one or more other components before use (e.g., concentrated or lyophilized form). The buffer can be any buffer, including but not limited to sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH of about 7 to about 10. In some embodiments, the kit includes one or more oligonucleotides corresponding to the guide sequence for insertion into a vector for operably linking the guide sequence and the regulatory element. In some embodiments, the kit includes a homologous recombination template polynucleotide.

[0083] In one embodiment, the present invention provides a method of using one or more elements of the CRISPR system.The CRISPR complex of the present invention provides an effective means of modifying target polynucleotide.The CRISPR complex of the present invention has a wide range of usefulness, for example, modifying (e.g., deleting, inserting, translocating, inactivating, activating) target polynucleotide in a large number of cell types.Therefore, the CRISPR complex of the present invention has a wide range of applications, for example, in gene therapy, drug screening, disease diagnosis, and prognosis.An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence that hybridizes to a target sequence in a target polynucleotide.The guide sequence is then bound to a tracr mate sequence that hybridizes to a tract sequence.

[0084] The target polynucleotide of the CRISPR complex can be any polynucleotide that is endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide can be a polynucleotide that remains in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence that codes for a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or junk DNA). Without being bound by theory, it is believed that the target sequence should associate with a PAM (protospacer adjacent motif); i.e., a short sequence that is recognized by the CRISPR complex. The exact sequence and length requirements for the PAM vary depending on the CRISPR enzyme used, but the PAM is typically a 2-5 base pair sequence adjacent to the protospacer (i.e., the target sequence). Examples of PAM sequences are provided in the Examples section below, and one of skill in the art can identify additional PAM sequences to be used for a given CRISPR enzyme.

[0085] Target polynucleotides for CRISPR complexes can include many of the disease-associated genes and polynucleotides and signaling biochemical pathway-associated genes and polynucleotides listed in U.S. Provisional Patent Applications Nos. 61 / 736,527 and 61 / 748,427 (both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION, filed December 12, 2012 and January 2, 2013, respectively), having Broad Reference Nos. BI-2011 / 008 / WSGR Docket Nos. 44063-701.101 and BI-2011 / 008 / WSGR Docket Nos. 44063-701.102, respectively, the entire contents of which are incorporated herein by reference in their entireties.

[0086] Examples of target polynucleotides include sequences related to signaling biochemical pathways, such as signaling biochemical pathway-related genes or polynucleotides. Examples of target polynucleotides include disease-related genes or polynucleotides. A "disease-related" gene or polynucleotide refers to any gene or polynucleotide that produces a transcription or translation product at an abnormal level or in an abnormal form in cells derived from diseased tissue compared to non-disease control tissue or cells. It can be a gene that becomes expressed at an abnormally high level; it can be a gene that becomes expressed at an abnormally low level, and the change in expression correlates with the occurrence and / or progression of disease. A disease-related gene also refers to a gene that is directly responsible for the pathogenesis of disease, or has a mutation or genetic variation that is in linkage disequilibrium with a gene that is responsible for the pathogenesis of disease. The transcription or translation product can be known or unknown, and can be at normal or abnormal levels.

[0087] Examples of disease-associated genes and polynucleotides are available from the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and the National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), and available on the World Wide Web.

[0088] Examples of disease-associated genes and polynucleotides are listed in Tables A and B. Disease-specific information is available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and the National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.) and available on the World Wide Web. Examples of signaling biochemical pathway-associated genes and polynucleotides are listed in Table C.

[0089] Mutations in these genes and pathways can result in inappropriate protein production or inappropriate amount of protein that affects function.Additional examples of genes, diseases and proteins are incorporated herein by reference from U.S. Provisional Patent Application No. 61 / 736,527, filed December 12, 2012, and U.S. Provisional Patent Application No. 61 / 748,427, filed January 2, 2013.Such genes, proteins and pathways can be the target polynucleotide of CRISPR complex.

[0090] [Table 1]

[0091] [Table 2]

[0092] [Table 3]

[0093] [Table 4]

[0094] [Table 5]

[0095]

Table 6

[0096]

Table 7

[0097]

Table 8

[0098]

Table 9

[0099]

Table 10

[0100]

Table 11

[0101]

Table 12

[0102]

Table 13

[0103]

Table 14

[0104]

Table 15

[0105] [Table 16]

[0106] [Table 17]

[0107] The present invention also relates to methods and compositions related to gene knockout, gene amplification and repair of specific mutations associated with DNA repeat instability and neurological diseases (Robert D. Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, Oct 13, 2011-Medical). Tandem repeat sequences of defined nature have been found to be responsible for more than 20 human diseases (New insights into repeat instability: role of RNA·DNA hybrids. McIvor EI, Polak U, Napierala M. RNA Biol. 2010 Sep-Oct; 7(5):551-8). The CRISPR-Cas system can be utilized to correct these defects in genomic instability.

[0108] A further aspect of the present invention relates to the use of the CRISPR-Cas system to correct the abnormalities of the EMP2A and EMP2B genes that have been identified as being associated with Lafora's disease. Lafora's disease is an autosomal recessive condition characterized by progressive myoclonic epilepsy that may begin as epileptic seizures in adolescence. Some cases of the disease may be caused by mutations in genes that have not yet been identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and ultimately death. Currently, there is no treatment that has proven effective against disease progression. Other genetic abnormalities associated with epilepsy can also be targeted by the CRISPR-Cas system, and the underlying genetics are further described in Genetics of Epilepsy and Genetic Epilepsies, edited by Giuliano Avanzini, Jeffrey L. Noebels, Mariani Foundation Paediatric Neurology:20;2009).

[0109] In yet another embodiment of the present invention, the CRISPR-Cas system can be used to correct eye defects resulting from several genetic mutations as further described in Genetic Diseases of the Eye, Second Edition, edited by Elias I. Traboulsi, Oxford University Press, 2012.

[0110] Some further aspects of the present invention relate to the correction of abnormalities associated with a wide range of genetic diseases, which are further described on the National Institutes of Health website (website at health.nih.gov / topic / GeneticDisorders) under the topic subsection Genetic Disorders. Genetic brain diseases include, but are not limited to, adrenoleukodystrophy, corpus callosum agenesis, Aicardi syndrome, Alper's disease, Alzheimer's disease, Barth syndrome, Batten disease, CADASIL, cerebellar degeneration, Fabry disease, Gerstmann-Straussler-Scheinker disease, Huntington's disease and other triplet repeat diseases, Leigh's disease, Lesch-Nyhan syndrome, Menkes disease, mitochondrial myopathy and NINDS colpocephaly. These diseases are further described on the National Institutes of Health website under the subsection Genetic Brain Disorders.

[0111] In some embodiments, the condition is neoplasia. In some embodiments, where the condition may be neoplasia, the gene to be targeted may be any of those listed in Table A (such as PTEN in this case). In some embodiments, the condition may be age-related macular degeneration. In some embodiments, the condition may be schizophrenia. In some embodiments, the condition may be a trinucleotide repeat disorder. In some embodiments, the condition may be fragile X syndrome. In some embodiments, the condition may be a secretase-associated disorder. In some embodiments, the condition may be a prion-associated disorder. In some embodiments, the condition may be ALS. In some embodiments, the condition may be drug addiction. In some embodiments, the condition may be autism. In some embodiments, the condition may be Alzheimer's disease. In some embodiments, the condition may be inflammation. In some embodiments, the condition may be Parkinson's disease.

[0112] Examples of proteins associated with Parkinson's disease include, but are not limited to, alpha-synuclein, DJ-1, LRRK2, PINK1, parkin, UCHL1, synphilin-1, and NURR1.

[0113] An example of a preference-related protein is ABAT.

[0114] Examples of inflammation-related proteins include, for example, monocyte chemoattractant protein-1 (MCP1) encoded by the Ccr2 gene, CC chemokine receptor type 5 (CCR5) encoded by the Ccr5 gene, IgG receptor IIB (FCGR2b, also known as CD32) encoded by the Fcgr2b gene, or Fc epsilon R1g (FCER1g) protein encoded by the Fcer1g gene.

[0115] Examples of cardiovascular disease-related proteins can include, for example, IL1B (interleukin 1, beta), XDH (xanthine dehydrogenase), TP53 (tumor protein p53), PTGIS (prostaglandin I2 (prostacyclin) synthase), MB (myoglobin), IL4 (interleukin 4), ANGPT1 (angiopoietin 1), ABCG8 (ATP-binding cassette, subfamily G (WHITE), member 8), or CTSK (cathepsin K).

[0116] Examples of Alzheimer's disease-related proteins include, for example, very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, ubiquitin-like modifier activating enzyme 1 (UBA1) encoded by the UBA1 gene, or NEDD8 activating enzyme E1 catalytic subunit protein (UBE1C) encoded by the UBA3 gene.

[0117] Examples of proteins associated with autism spectrum disorders include, for example, benzodiazepine receptor (peripheral) associated protein 1 (BZRAP1) encoded by the BZRAP1 gene, AF4 / FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also called MFR2), fragile X mental retardation autosomal homolog 1 protein (FXR1) encoded by the FXR1 gene, or fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene.

[0118] Examples of proteins associated with macular degeneration include, for example, the ATP-binding cassette subfamily A (ABC1) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoprotein E protein (APOE) encoded by the APOE gene, or the chemokine (CC motif) ligand 2 protein (CCL2) encoded by the CCL2 gene.

[0119] Examples of proteins associated with schizophrenia include NRG1, ErbB4, CPLX1, TPH1, TPH2, NRXN1, GSK3A, BDNF, DISC1, GSK3B, and combinations thereof.

[0120] Examples of proteins involved in tumor suppression include, for example, ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 associated), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch1, Notch2, Notch3, or Notch4.

[0121] Examples of proteins associated with secretase disorders can include, for example, PSENEN (presenilin enhancer 2 homolog (C. elegans)), CTSB (cathepsin B), PSEN1 (presenilin 1), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharyngeal defect 1 homolog B (C. elegans)), PSEN2 (presenilin 2 (Alzheimer's disease 4)), or BACE1 (beta site APP cleavage enzyme 1).

[0122] Examples of proteins associated with amyotrophic lateral sclerosis include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor B). Factor C), and any combination thereof.

[0123] Examples of proteins associated with prion diseases can include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.

[0124] Examples of proteins associated with neurodegenerative pathology in prion disorders can include, for example, A2M (alpha-2-macroglobulin), AATF (apoptosis antagonistic transcription factor), ACPP (prostatic acid phosphatase), ACTA2 (aortic smooth muscle actin alpha 2), ADAM22 (ADAM metallopeptidase domain), ADORA3 (adenosine A3 receptor), or ADRA1D (alpha-1D adrenergic receptor for alpha-1D adrenergic receptor).

[0125] Examples of proteins associated with immunodeficiency include, for example, A2M [alpha-2-macroglobulin]; AANAT [arylalkylamine N-acetyltransferase]; ABCA1 [ATP-binding cassette subfamily A (ABC1), member 1]; ABCA2 [ATP-binding cassette subfamily A (ABC1), member 2]; or ABCA3 [ATP-binding cassette subfamily A (ABC1), member 3].

[0126] Examples of proteins associated with trinucleotide repeat disorders include, for example, AR (androgen receptor), FMR1 (Fragile X Mental Retardation 1), HTT (Huntington), or DMPK (Myotonic Dystrophy Protein Kinase), FXN (Frataxin), ATXN2 (Ataxin 2).

[0127] Examples of proteins associated with neurotransmission disorders include, for example, SST (somatostatin), NOS1 (nitric oxide synthase 1 (neuronal type)), ADRA2A (adrenergic alpha-2A receptor), ADRA2C (adrenergic alpha-2C receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxytryptamine (serotonin) receptor 2C).

[0128] Examples of neurodevelopment-related sequences include, for example, A2BP1 [ataxin 2-binding protein 1], AADAT [aminoadipate aminotransferase], AANAT [arylalkylamine N-acetyltransferase], ABAT [4-aminobutyrate aminotransferase], ABCA1 [ATP-binding cassette subfamily A (ABC1) member 1], or ABCA13 [ATP-binding cassette subfamily A (ABC1) member 13].

[0129] Further examples of preferred conditions treatable by the system of the present invention may be selected from: Alcardi-Goutières syndrome; Alexander disease; Allan-Herndon-Dudley syndrome; POLG-related disorders; alpha-mannosidosis (types II and III); Alström syndrome; Angelman syndrome; ataxia-telangiectasia; neuronal ceroid lipofuscinosis; beta-thelassemia; bilateral optic atrophy and (infantile) optic atrophy type 1; retinoblastoma (bilateral); Canavan disease; cerebro-ocular-facial-skeletal syndrome 1 [COFS1]; cerebrotendinous xanthomas. disease;Cornelia de Lange syndrome;MAPT-related disorder;Hereditary prion disease;Dravet syndrome;Early-onset familial Alzheimer's disease;Friedreich ataxia [FRDA];Flins syndrome;Fucosidosis;Fukuyama-type congenital muscular dystrophy;Galactosialidosis;Gaucher disease;Organic acidemias;Hemophagocytic lymphohistiocytosis;Hutchinson-Gilford progeria syndrome;Mucolipidosis type II;Infantile free sialic acid storage disease;PLA2G6-associated neurodegeneration;Jervell-Lange-Nielsen syndrome;Junctional epidermolysis bullosa;Huntington's disease;Krabbe disease (infantile form) ;mitochondrial DNA-related Leigh syndrome and NARP;Lesch-Nyhan syndrome;LIS1-related lissencephaly;Low syndrome;Maple syrup urine disease;MECP2 duplication syndrome;ATP7A-related copper transport disorder;LAMA2-related muscular dystrophy;Arylsulfatase A deficiency;Mucopolysaccharidosis types I, II, or III;Peroxisomal biogenesis disorders, Zellweger syndrome spectrum;Neurodegeneration with cerebral iron storage disease;Acid sphingomyelinase deficiency;Niemann-Pick disease type C;Glycine encephalopathy;ARX-related disorders;Urea cycle disorders;COL1A1 / 2-related vertebral dysplasia;mitochondrial DNA deletion syndrome;PLP1-related disorder;Perry syndrome;McDermott syndrome;Glycogen storage disease type II (Pompe disease) (infantile form);MAPT-related disorder;MECP2-related disorder;Rhizome punctata chondrodysplasia type 1;Roberts syndrome;Sandhoff disease;Schindler disease type 1;Adenosine deaminase deficiency;Smith-Lemli-Opitz syndrome;Spinal muscular atrophy;Infantile-onset spinocerebellar ataxia;Hexosaminidase A deficiency;Thalatogenic dysplasia type 1;Collagen VI-related disorder;Usher syndrome type I;Congenital muscular dystrophy;Wolf-Hirschhorn syndrome; lysosomal acid lipase deficiency; and xeroderma pigmentosum.

[0130] Obviously, it is envisaged that the system of the present invention can be used to target any polynucleotide sequence of interest.Some examples of pathologies or diseases that can be usefully treated using the system of the present invention are included in the above table, and examples of genes currently associated with these pathologies are also provided in the table.However, the genes exemplified are not exclusive. EXAMPLES

[0131] The following examples are given for the purpose of illustrating various embodiments of the present invention, and are not meant to limit the present invention in any manner. The examples, together with the methods described herein, are representative and illustrative of currently preferred embodiments, and are not intended to be limitations on the scope of the present invention. Modifications thereof and other uses encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

[0132] Example 1: CRISPR complex activity in the nucleus of a eukaryotic cell An exemplary type II CRISPR system is the type II CRISPR locus from Streptococcus pyogenes SF370, which contains a cluster of four genes Cas9, Cas1, Cas2, and Csn1, and two non-coding RNA elements, tracrRNA and a characteristic array of repeat sequences (direct repeats) spaced by short stretches of non-repetitive sequences (spacers, each about 30 bp). In this system, targeted DNA double-strand breaks (DSBs) are generated in four successive steps (Figure 2A). First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of the pre-crRNA, which are then processed into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of the target DNA upstream of the PAM to create a DSB within the protospacer (Figure 2A). This example describes an exemplary process of adapting this RNA programmable nuclease system to direct CRISPR complex activity in the nucleus of a eukaryotic cell.

[0133] Cell culture and transfection The human embryonic kidney (HEK) cell line HEK293FT (Life Technologies) was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2 mM GlutaMAX (Life Technologies), 100 U / mL penicillin, and 100 μg / mL streptomycin at 37° C. with 5% CO2 incubation. The mouse neuro2A (N2A) cell line (ATCC) was maintained in DMEM supplemented with 5% fetal bovine serum (HyClone), 2 mM GlutaMAX (Life Technologies), 100 U / mL penicillin, and 100 μg / mL streptomycin at 37° C. with 5% CO2.

[0134] HEK293FT or N2A cells were seeded in 24-well plates (Corning) at a density of 200,000 cells per well one day before transfection. Cells were transfected using Lipofectamine2000 (Life Technologies) according to the manufacturer's recommended protocol. A total of 800 ng of plasmid was used for each well of the 24-well plate.

[0135] Surveyor assay and sequencing analysis of genomic alterations HEK293FT or N2A cells were transfected with the above plasmid DNA. After transfection, cells were incubated at 37°C for 72 hours before genomic DNA was extracted. Genomic DNA was extracted using QuickExtract DNA extraction kit (Epicentre) according to the manufacturer's protocol. Briefly, cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes. Extracted genomic DNA was processed immediately or stored at -20°C.

[0136] Genomic regions surrounding the CRISPR target sites for each gene were PCR amplified and products were purified using QiaQuick Spin Columns (Qiagen) according to the manufacturer's protocol. A total of 400 ng of purified PCR products were mixed with 2 μl of 10× Taq polymerase PCR buffer (Enzymatics), brought to a final volume of 20 μl with ultrapure water, and subjected to a reannealing process to allow heteroduplex formation: 95°C for 10 min, ramping from 95°C to 85°C at -2°C / s, 85°C to 25°C at -0.25°C / s, and holding at 25°C for 1 min. After reannealing, products were treated with Surveyor Nuclease and Surveyor Enhancer S (Transgenomics) according to the manufacturer's recommended protocol and analyzed on 4-20% Novex TBE polyacrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 min and imaged with a Gel Doc gel imaging system (Bio-rad). Quantitation was based on relative band intensity as a measure of the percentage of cleaved DNA. Figure 7 provides a schematic description of the Surveyor assay.

[0137] Restriction fragment length polymorphism assay for detection of homologous recombination HEK293FT and N2A cells were transfected with plasmid DNA and incubated at 37°C for 72 hours before genomic DNA extraction as described above. Target genomic regions were PCR amplified using primers outside the homology arms of the homologous recombination (HR) template. PCR products were separated on a 1% agarose gel and extracted with a MinElute Gel Extraction Kit (Qiagen). Purified products were digested with HindIII (Fermentas) and analyzed on a 6% Novex TBE polyacrylamide gel (Life Technologies).

[0138] RNA secondary structure prediction and analysis RNA secondary structure prediction was performed using the online web server RNAfold developed at the Institute for Theoretical Chemistry at the University of Vienna, using a centroid structure prediction algorithm (see, e.g., A. R. Gruber et al., 2008, Cell 106(1):23-24; and P. A. Carr and G. M. Church, 2009, Nature Biotechnology 27(12):1151-62).

[0139] RNA purification HEK293FT cells were maintained and transfected as described above. Cells were harvested by trypsinization and then washed in phosphate-buffered saline (PBS). Total cellular RNA was extracted with TRI Reagent (Sigma) according to the manufacturer's protocol. Extracted total RNA was quantified using Naonodrop (Thermo Scientific) and normalized to the same concentration.

[0140] Northern blot analysis of crRNA and tracrRNA expression in mammalian cells RNA was mixed with an equal volume of 2x loading buffer (Ambion), heated to 95°C for 5 min, chilled on ice for 1 min, and then loaded onto an 8% denaturing polyacrylamide gel (SequaGel, National Diagnostics) after pre-running the gel for at least 30 min. Samples were electrophoresed for 1.5 h at 40 W limit. RNA was then transferred to Hybond N+ membrane (GE Healthcare) at 300 mA in a semi-dry transfer apparatus (Bio-rad) for 1.5 h at room temperature. RNA was crosslinked to the membrane using the autocrosslink button on a Stratalinker (Stratagene) of a Stratagene UV Crosslinker. Membranes were prehybridized in ULTRAhyb-oligo hybridization buffer (Ambion) for 30 min at 42°C with rotation, then probe was added and hybridized overnight. Probes were ordered from IDT and labeled with [gamma-32P]ATP (Perkin Elmer) using T4 polynucleotide kinase (New England Biolabs). Membranes were washed once for 1 min with prewarmed (42°C) 2xSSC, 0.5% SDS, then washed twice for 30 min at 42°C. Membranes were exposed to a phosphor screen for 1 h or overnight at room temperature, then scanned with a phosphorimager (Typhoon).

[0141] Bacterial CRISPR system construction and evaluation CRISPR locus elements, including tracrRNA, Cas9, and leader, were PCR amplified from Streptococcus pyogenes SF370 genomic DNA with flanking homology arms for Gibson Assembly. Two BsaI type IIS sites were introduced between the two direct repeats to facilitate easy insertion of the spacer (Figure 8). The PCR product was cloned downstream of the tet promoter into EcoRV-digested pACYC184 using Gibson Assembly Master Mix (NEB). The last 50 bp of Csn2 was omitted, excluding other endogenous CRISPR system elements. Oligos encoding the spacer with complementary overhangs (Integrated DNA Technology) were cloned into BsaI-digested vector pDC000 (NEB) and then ligated with T7 ligase (Enzymatics) to generate pCRISPR plasmids. Challenge plasmid containing spacer with PAM expression in mammalian cells (expression construct as illustrated in FIG. 6A, with functionality determined by the results of Surveyor assay shown in FIG. 6B). The transcription start site is labeled as +1, and the transcription terminator and the sequence probed by Northern blot are also shown. Expression of processed tracrRNA was also confirmed by Northern blot. FIG. 6C shows the results of Northern blot analysis of total RNA extracted from 293FT cells transfected with long or short tracrRNA and U6 expression construct carrying SpCas9 and DR-EMX1(1)-DR. The left and right panels are from 293FT cells transfected without or with SpRNase III, respectively. U6 indicates the loading control blotted with a probe targeting human U6 snRNA. Transfection of the short tracrRNA expression construct resulted in sufficient levels of the processed form of tracrRNA (approximately 75 bp). Very little long tracrRNA was detected on Northern blots.

[0142] To promote accurate transcription initiation, an RNA polymerase III-based U6 promoter was selected to drive the expression of tracrRNA (Figure 2C). Similarly, a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr mate sequence"; Figure 2C). The first spacer was designed to target a 33 base pair (bp) target site (a 30 bp protospacer and a 3 bp CRISPR motif (PAM) sequence that fulfills the NGG recognition motif of Cas9) in the human EMX1 locus, a key gene in the development of the cerebral cortex (Figure 2C).

[0143] To test whether heterologous expression of the CRISPR system (SpCas9, SpRNaseIII, tracrRNA, and pre-crRNA) in mammalian cells could achieve targeted mammalian chromosome cleavage, HEK293FT cells were transfected with a combination of CRISPR components. Because DSBs in mammalian nuclei are repaired in part by the non-homologous end joining (NHEJ) pathway, which results in the formation of indels, the Surveyor assay was used to detect potential cleavage activity at the target EMX1 locus (Figure 7) (see, e.g., Guschin et al., 2010, Methods Mol Biol 649:247). Co-transfection of all four CRISPR components could induce cleavage of up to 5.0% of the protospacers (see Figure 2D). Co-transfection of all CRISPR components except SpRNase III also induced indels in up to 4.7% of the protospacers, suggesting that there may be endogenous mammalian RNases, such as the related Dicer and Drosha enzymes, that may assist in crRNA maturation. Removal of any of the remaining three components abolished the genome cleavage activity of the CRISPR system (Figure 2D). Sanger sequencing of amplicons containing the target locus confirmed the cleavage activity; five mutant alleles (11.6%) were found among 43 sequenced clones. Similar experiments using various guide sequences yielded indel percentages as high as 29% (see Figures 3-6, 10, and 11). These results define a three-component system for efficient CRISPR-mediated genome modification in mammalian cells. To optimize cleavage efficiency, we also tested whether different isoforms of tracrRNA affect cleavage efficiency and found that in this exemplary system, only the short (89 bp) transcript form could mediate cleavage of the human EMX1 genomic locus (Figure 6B).

[0144] Figure 12 provides additional Northern blot analysis of crRNA processing in mammalian cells. Figure 12A illustrates a schematic showing an expression vector for a single spacer (DR-EMX1(1)-DR) flanked by two direct repeats. The 30 bp spacer targeting human EMX1 locus protospacer 1 (see Figure 6) and the direct repeat sequence are shown in the lower sequence of Figure 12A. The line indicates the region where the reverse complement sequence is used to generate a Northern blot probe for EMX1(1) crRNA detection. Figure 12B shows Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression construct carrying DR-EMX1(1)-DR. The left and right panels are from 293FT cells transfected without or with SpRNase III, respectively. DR-EMX1(1)-DR was processed to mature crRNA only in the presence of SpCas9, and the short tracrRNA was not dependent on the presence of SpRNase III. The mature crRNA detected from transfected 293FT total RNA was approximately 33 bp, shorter than the 39-42 bp mature crRNA from S. pyogenes. These results demonstrate that the CRISPR system can be transplanted into eukaryotic cells and reprogrammed to promote cleavage of endogenous mammalian target polynucleotides.

[0145] Figure 2 illustrates the bacterial CRISPR system described in this example. Figure 2A illustrates a schematic diagram showing the CRISPR locus 1 from Streptococcus pyogenes SF370 and the proposed mechanism of CRISPR-mediated DNA cleavage by this system. Mature crRNA processed from the direct repeat-spacer array directs Cas9 to a genomic target consisting of a complementary protospacer and a protospacer adjacent motif (PAM). Upon target-spacer base pairing, Cas9 mediates a double-stranded break in the target DNA. Figure 2B illustrates the engineering of S. pyogenes Cas9 (SpCas9) and RNase III (SpRNase III) with a nuclear localization signal (NLS) to enable transport into mammalian nuclei. Figure 2C illustrates mammalian expression of SpCas9 and SpRNase III driven by a constitutive EF1a promoter and tracrRNA and pre-crRNA arrays (DR-spacer-DR) driven by the RNAPol3 promoter U6 to promote accurate transcription initiation and termination. A protospacer from the human EMX1 locus with sufficient PAM sequence is used as a spacer in the pre-crRNA array. Figure 2D illustrates surveyor nuclease assays for SpCas9-mediated small insertions and deletions. SpCas9 was expressed with or without SpRNase III, tracrRNA, and pre-crRNA arrays carrying the EMX1 targeting spacer. Figure 2E illustrates a schematic representation of base pairing between the target locus and EMX1 targeting crRNA, as well as an exemplary chromatogram showing a microdeletion adjacent to the SpCas9 cleavage site. Figure 2F illustrates mutant alleles identified from sequencing analysis of 43 clonal amplicons showing various microinsertions and deletions. Dotted lines indicate deleted bases, unaligned or mismatched bases indicate insertions or mutations. Scale bar = 10 μm.

[0146] To further simplify the three-component system, a chimeric crRNA-tracrRNA hybrid design can be adapted in which the mature crRNA (including guide sequence) is fused to a partial tracrRNA via a stem-loop to mimic the natural crRNA:tracrRNA duplex. To increase the co-delivery efficiency, a bicistronic expression vector was created to drive the co-expression of chimeric RNA and SpCas9 in transfected cells. In parallel, a bicistronic vector was used to express pre-crRNA (DR-guide sequence-DR) ​​together with SpCas9 to guide its processing into crRNA and to express tracrRNA separately (compare top and bottom panels in Figure 11B). Figure 8 provides a schematic illustration of the bicistronic expression vector for pre-crRNA arrays with hSpCas9 (Figure 8A) or chimeric crRNA (represented by a short line downstream of the guide sequence insertion site and upstream of the EF1α promoter in Figure 8B), showing the localization of the various elements and the location of guide sequence insertion. The expanded sequence around the location of the guide sequence insertion site in FIG. 8B also shows the partial DR sequence (GTTTTAGAGCTA) (SEQ ID NO: 11) and the partial tracrRNA sequence (TAGCAAGTTAAAATAAGGCTAGTCCGTTTTT) (SEQ ID NO: 12). The guide sequence can be inserted between the BbsI sites using annealed oligonucleotides. The sequence design for the oligonucleotides is shown below the schematic illustration in FIG. 8, and the appropriate ligation adapters are shown. WPRE stands for Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element. The efficiency of chimeric RNA-mediated cleavage was tested by targeting the same EMX1 locus described above. Using both Surveyor assays and Sanger sequencing of the amplicons, applicants confirmed that the chimeric RNA design promoted cleavage of the human EMX1 locus with a modification rate of about 4.7% (FIG. 3).

[0147] The generalizability of CRISPR-mediated cleavage in eukaryotic cells was tested by targeting additional genomic loci in both human and mouse cells by designing chimeric RNAs targeting multiple sites in human EMX1 and PVALB, and mouse Th loci. Figure 13 illustrates the selection of protospacers in several additional targeted human PVALB (Figure 13A) and mouse Th (Figure 13B) loci. A schematic diagram of the location of the three protospacers within the loci and their respective last exons is provided. The underlined sequences include the 30 bp protospacer sequence and the 3 bp at the 3' end corresponding to the PAM sequence. The protospacers on the sense and antisense strands are shown above and below the DNA sequence, respectively. Modification rates of 6.3% and 0.75% were achieved for human PVALB and mouse Th loci, respectively, demonstrating the broad applicability of the CRISPR system in modifying different loci across multiple organisms (Figure 5). While cleavage was detected for only one of the three spacers for each locus using the chimeric construct, when using the co-expressed pre-crRNA configuration, all target sequences were cleaved with an efficiency of indel generation reaching 27% (Figures 6 and 13).

[0148] Figure 11 provides further illustration that SpCas9 can be reprogrammed to target multiple genomic loci in mammalian cells. Figure 11A provides a schematic of the human EMX1 locus showing the localization of the five protospacers indicated by the underlined sequences. Figure 11B provides a schematic of the pre-crRNA / trcrRNA complex showing the hybridization between the direct repeat regions of the pre-crRNA and tracrRNA (top) and a schematic of the chimeric RNA design including a 20 bp guide sequence and a tracr mate and tracr sequence consisting of partial direct repeats and tracrRNA sequences hybridized to a hairpin structure (bottom). The results of a Surveyor assay comparing the efficacy of Cas9-mediated cleavage at five protospacers in the human EMX1 locus are illustrated in Figure 11C. Either the processed pre-crRNA / tracrRNA complex (crRNA) or chimeric RNA (chiRNA) is used to target each protospacer.

[0149] Because RNA secondary structure can be important for intermolecular interactions, we used a structure prediction algorithm based on minimum free energy and Boltzmann weighted structure ensemble to compare the predicted secondary structures of all guide sequences used in genome targeting experiments (see, e.g., Gruber et al., 2008, Nucleic Acids Research, 36:W70). The analysis revealed that in most cases, effective guide sequences in the chimeric crRNA context were substantially free of secondary structure motifs, while ineffective guide sequences were more likely to form internal secondary structures that could interfere with base pairing with the target protospacer DNA. Therefore, it is conceivable that variability in spacer secondary structure may affect the efficiency of CRISPR-mediated interference when using chimeric crRNA.

[0150] Further vector designs for SpCas9 are shown in Figure 22, which illustrates a single expression vector incorporating a U6 promoter linked to an insertion site for a guide oligo, and a Cbh promoter linked to the SpCas9 coding sequence. The vector shown in Figure 22b contains the tracrRNA coding sequence linked to the H1 promoter.

[0151] In bacterial assays, all spacers promoted efficient CRISPR interference (Figure 3C). These results suggest that there may be additional factors that affect the efficiency of CRISPR activity in mammalian cells.

[0152] To investigate the specificity of CRISPR-mediated cleavage, the effect of single nucleotide mutations in the guide sequence on protospacer cleavage in mammalian genomes was analyzed using a series of EMX1-targeting chimeric crRNAs with single point mutations (Figure 3A). Figure 3B illustrates the results of a Surveyor nuclease assay comparing the cleavage efficiency of Cas9 when paired with different mutant chimeric RNAs. Single base mismatches up to 12 bp 5' of the PAM virtually abolished genome cleavage by SpCas9, while spacers with mutations at further upstream positions retained activity against the original protospacer target (Figure 3B). Besides the PAM, SpCas9 has single base specificity within the last 12 bp of the spacer. Furthermore, CRISPR can mediate genome cleavage as efficiently as a pair of TALE nucleases (TALENs) targeting the same EMX1 protospacer. FIG. 3C provides a schematic showing the design of TALENs targeting EMX1, and FIG. 3D shows a Surveyor gel comparing the efficiency of TALENs and Cas9 (n=3).

[0153] Having established a set of components to achieve CRISPR-mediated gene editing in mammalian cells through the error-prone NHEJ mechanism, we tested the ability of CRISPR to stimulate homologous recombination (HR), a high-fidelity gene repair pathway to create precise edits in the genome. Wild-type SpCas9 can mediate site-specific DSBs that can be repaired through both NHEJ and HR. Furthermore, we engineered an aspartic acid to alanine substitution (D10A) in the RuvC I catalytic domain of SpCas9 to convert the nuclease into a nickase (SpCas9n; illustrated in Figure 4A) (see, e.g., Sapranausaks et al., 2011, Nucleic Acids Research, 39:9275; Gasiunas et al., 2012, Proc. Natl. Acad. Sci. USA, 109:E2579), so that nicked genomic DNA undergoes high-fidelity homology-directed repair (HDR). Surveyor assay confirmed that SpCas9n did not generate indels in the EMX1 protospacer target. As illustrated in Figure 4B, co-expression of EMX1-targeting chimeric crRNA with SpCas9 generated indels in the target site, whereas co-expression with SpCas9n did not (n=3). Furthermore, sequencing of 327 amplicons did not detect any indels induced by SpCas9n. The same locus was selected and CRISPR-mediated HR was tested by co-transfecting HEK293FT cells with chimeric RNA targeting EMX1, hSpCas9 or hSpCas9n, and the HR template to introduce a pair of restriction sites (HindIII and NheI) near the protospacer. Figure 4C provides a schematic illustration of the HR strategy, along with the relative localization of the recombination sites and primer annealing sequences (arrows). SpCas9 and SpCas9n indeed catalyzed the integration of the HR template into the EMX1 gene.PCR amplification of the target region followed by restriction digestion with HindIII revealed cleavage products corresponding to the predicted fragment sizes (arrows in the restriction fragment length polymorphism gel analysis shown in Figure 4D), and SpCas9 and SpCas9n mediated similar levels of HR efficiency. Applicants further confirmed HR using Sanger sequencing of genomic amplicons (Figure 4E). These results demonstrate the utility of CRISPR to facilitate targeted gene insertion in mammalian genomes. Given the 14 bp target specificity of wild-type SpCas9 (12 bp from the spacer and 2 bp from the PAM), the availability of nickase may significantly reduce the possibility of off-target modifications, as single-stranded breaks are not substrates for the error-prone NHEJ pathway.

[0154] An expression construct mimicking the natural architecture of the CRISPR locus with an array spacer (Figure 2A) was constructed to test the possibility of multiplexed sequence targeting. Using a single CRISPR array encoding a pair of EMX1 and PVALB targeting spacers, efficient cleavage at both loci was detected (Figure 4F, showing both a schematic design of the crRNA array and a Surveyor blot showing efficient mediation of cleavage). Targeted deletion of a larger genomic region through simultaneous DSBs using spacers to two targets in EMX1 spaced by 119 bp was also tested, and a deletion efficiency of 1.6% (3 out of 182 amplicons; Figure 4G) was detected. This demonstrates that the CRISPR system can mediate multiplexed editing within a single genome.

[0155] Example 2: CRISPR-based modifications and alternatives The skill of using RNA to program sequence-specific DNA cleavage defines a new class of genome engineering tools for various research and industrial applications. Some aspects of the CRISPR system can be further improved to increase the efficiency and versatility of CRISPR targeting. Optimal Cas9 activity may depend on the availability of free Mg2+ at levels higher than those present in mammalian nuclei (see, e.g., Jinek et al., 2012, Science, 337:816), and the preference for NGG motifs immediately downstream of the protospacer limits targeting ability to an average of every 12 bp in the human genome (Figure 9, evaluating both the positive and negative strands of human chromosomal sequences). Some of these constraints can be overcome by taking advantage of the diversity of CRISPR loci across microbial metagenomes (see, e.g., Makarova et al., 2011, Nat Rev Microbiol, 9:467). Other CRISPR loci can be transplanted into mammalian cell environments by methods similar to those described in Example 1. For example, FIG. 10 illustrates the adaptation of a type II CRISPR system from CRISPR1 of Streptococcus thermophilus LMD-9 for heterologous expression in mammalian cells to achieve CRISPR-mediated genome editing. FIG. 10A provides a schematic illustration of CRISPR1 of S. thermophilus LMD-9. FIG. 10B illustrates the design of an expression system for the S. thermophilus CRISPR system. Human codon-optimized hStCas9 is expressed using a constitutive EF1α promoter. Mature versions of tracrRNA and crRNA are expressed using a U6 promoter to facilitate accurate transcription initiation. Sequences from mature crRNA and tracrRNA are illustrated. A single base, indicated by a lowercase "a" in the crRNA sequence, is used to remove the polyU sequence that functions as an RNApolIII transcription terminator. FIG. 10C provides a schematic showing guide sequences targeting the human EMX1 locus.Figure 10D shows the results of hStCas9-mediated cleavage in the target locus using the Surveyor assay. RNA guide spacers 1 and 2 induced 14% and 6.4%, respectively. A statistical analysis of the cleavage activity across biological replicates at these two protospacer sites is also provided in Figure 5. Figure 14 provides a schematic of additional protospacers and corresponding PAM sequence targets of the S. thermophilus CRISPR system in the human EMX1 locus. Two protospacer sequences are highlighted and their corresponding PAM sequences that fulfill the NNAGAAW motif are indicated by underlining 3' to the corresponding highlighted sequence. Both protospacers target the antisense strand.

[0156] Example 3: Sample target sequence selection algorithm Design a software program to identify candidate CRISPR target sequences on both strands of the input DNA sequence based on the desired guide sequence length and CRISPR motif sequence (PAM) for a given CRISPR enzyme. For example, the target site for Cas9 from Streptococcus pyogenes (S. pyogenes) can be identified by searching for 5'-Nx-NGG-3' on both the input sequence and the reverse complement of the input with the PAM sequence NGG. Similarly, the target site for Cas9 of S. thermophilus (S. thermophilus) CRISPR1 can be identified by searching for 5'-Nx-NNAGAAW-3' on both the input sequence and the reverse complement of the input with the PAM sequence NNAGAAW. Similarly, target sites for Cas9 in S. thermophilus CRISPR3 can be identified by searching for 5'-Nx-NGGNG-3' on both the input sequence and the reverse complement of the input, with the PAM sequence NGGNG. The value "x" in Nx can be fixed by the program or user-defined, e.g., 20.

[0157] Since multiple occurrences of a DNA target site in a genome can result in non-specific genome editing, after identifying all potential sites, the program filters out sequences based on the number of times the sequence appears in the relevant reference genome. For those CRISPR enzymes whose sequence specificity is determined by a "seed" sequence, e.g., 11-12 bp 5' from the PAM sequence, including the PAM sequence itself, the filtering step can be based on the seed sequence. Thus, to avoid editing at additional genomic loci, the results are filtered based on the number of occurrences of the seed:PAM sequence in the relevant genome. The user can be allowed to select the length of the seed sequence. The user can also be allowed to define the number of occurrences of the seed:PAM sequence in the genome for the purpose of filtering. The default is to screen for unique sequences. The filtration level is altered by changing both the length of the seed sequence and the number of occurrences of the sequence in the genome. The program can additionally or alternatively provide a sequence of a guide sequence that is complementary to the reported target sequence by providing the reverse complement of the identified target sequence. An exemplary visualization of some target sites in the human genome is provided in FIG. 18.

[0158] Further details of methods and algorithms for optimizing sequence selection can be found in U.S. Patent Application No. 61 / 064,798 (Attorney Docket No. 44790.11.2022; Broad Reference No. BI-2012 / 084), which is incorporated herein by reference.

[0159] Example 4: Evaluation of multiple chimeric crRNA-tracrRNA hybrids This example describes the results obtained for chimeric RNAs (chiRNAs; containing guide, tracr mate, and tracr sequences in a single transcript) with tracr sequences incorporating different lengths of wild-type tracrRNA sequences. Figure 16a illustrates a schematic diagram of the bicistronic expression vector for chimeric RNA and Cas9. Cas9 is driven by the CBh promoter and the chimeric RNA is driven by the U6 promoter. The chimeric guide RNA consists of a 20 bp guide sequence (N) linked to a truncated tracr sequence (extending from the first "U" on the lower strand to the end of the transcript) at various positions as indicated. The guide and tracr sequences are separated by the tracr mate sequence GUUUUAGAGCUA (SEQ ID NO: 13) followed by the loop sequence GAAA. The results of the SURVEYOR assay for Cas9-mediated indels at the human locus EMX1 and the PVALB locus are illustrated in Figures 16b and 16c, respectively. The arrows indicate the predicted SURVEYOR fragments. ChiRNAs are indicated by their "+n" designation, and crRNA refers to hybrid RNAs in which the guide and tracr sequences are expressed as separate transcripts. Quantification of these results, performed in triplicate, is shown by histograms in Figures 17a and 17b, corresponding to Figures 16b and 16c, respectively ("ND" indicates no indels detected). Protospacer IDs and their corresponding genomic targets, protospacer sequences, PAM sequences, and strand localization are provided in Table D. Guide sequences were designed to be complementary to the entire protospacer sequence in the case of separate transcripts in the hybrid system, or only to the underlined portion in the case of chimeric RNAs.

[0160] [Table 18]

[0161] Further details for optimizing guide sequences can be found in U.S. Patent Application No. 61 / 836,127 (Attorney Docket No. 44790.08.2022; Broad Reference BI-2013 / 004G), which is incorporated by reference herein.

[0162] We first targeted three sites within the EMX1 locus in human HEK293FT cells. The genome modification efficiency of each chiRNA was assessed using the SURVEYOR nuclease assay, which detects mutations resulting from DNA double-strand breaks (DSBs) and their subsequent repair by the non-homologous end joining (NHEJ) DNA damage repair pathway. Constructs designated as chiRNA(+n) indicate that up to +n nucleotides of wild-type tracrRNA are included in the chimeric RNA construct, with values ​​of 48, 54, 67, and 85 for n being used. Chimeric RNAs containing longer fragments of wild-type tracrRNA (chiRNA(+67) and chiRNA(+85)) mediated DNA cleavage at all three EMX1 target sites, with chiRNA(+85) in particular demonstrating significantly higher levels of DNA cleavage than the corresponding crRNA / tracrRNA hybrids expressing guide and tracr sequences in separate transcripts (Figures 16b and 17a). Two sites in the PVALB locus that did not produce detectable cleavage in the hybrid system (guide and tracr sequences expressed as separate transcripts) were also targeted using chiRNA. chiRNA(+67) and chiRNA(+85) could mediate significant cleavage in the two PVALB protospacers (Figures 16c and 17b). A consistent increase in genome modification efficiency with increasing tracr sequence length was observed for all five targets in the EMX1 and PVALB loci. Without being bound by any theory, the secondary structure formed by the 3' end of tracrRNA may play a role in enhancing the rate of CRISPR complex formation.

[0163] Example 5: Cas9 diversity CRISPR-Cas systems are adaptive immune mechanisms against invading exogenous DNA used by a variety of species ranging from bacteria to archaea. Type II CRISPR-Cas9 systems consist of a set of genes encoding proteins responsible for the "getting" of foreign DNA into the CRISPR locus, and a set of genes encoding the "execution" of the DNA cleavage mechanism; these include a DNA nuclease (Cas9), a non-coding transactivating crRNA (tracrRNA), and an array of spacers derived from the foreign DNA flanked by direct repeats (crRNA). Upon maturation by Cas9, the tracRNA and crRNA duplex guide the Cas9 nuclease to the target DNA sequence defined by the spacer guide sequence, and mediate a double-stranded break in DNA near a short sequence motif in the target DNA required for cleavage and specific to each CRISPR-Cas system. Type II CRISPR-Cas systems are found throughout the bacterial kingdom and are highly diverse in Cas9 protein sequence and size, tracrRNA and crRNA direct repeat sequences, genomic organization of their elements, and motif requirements for targeted cleavage. A given species may have multiple distinct CRISPR-Cas systems.

[0164] Applicants evaluated 207 putative Cas9s from bacterial species that were identified based on sequence homology to known Cas9s and orthologous structures to known subdomains, e.g., the HNH endonuclease domain and the RuvC endonuclease domain [information from Eugene Koonin and Kira Makarova]. Phylogenetic analysis based on protein sequence conservation of this set revealed five families of Cas9s, including three groups of large Cas9s (~1400 amino acids) and two groups of small Cas9s (~1100 amino acids) (see Figures 19 and 20A-F).

[0165] Further details of Cas9 and mutations of the Cas9 enzyme to convert it into a nickase or DNA binding protein and uses of Cas9 with altered functionality can be found in U.S. Patent Application Nos. 61 / 836,101 and 61 / 835,936 (Attorney Docket Nos. 44790.09.2022 and 4790.07.2022, respectively, and Broad References BI-2013 / 004E and BI-2013 / 004F), which are incorporated herein by reference.

[0166] Example 6: Cas9 orthologs Applicants analyzed Cas9 orthologs to identify related PAM sequences and corresponding chimeric guide RNAs. Having an expanded set of PAMs provides broader targeting across the genome and also significantly increases the number of unique target sites, offering the potential to identify novel Cas9s with increased levels of specificity in the genome.

[0167] The specificity of Cas9 orthologs can be evaluated by testing the ability of each Cas9 to tolerate mismatches between guide RNA and its DNA target. For example, the specificity of SpCas9 was characterized by testing the effect of mutations in guide RNA on cleavage efficiency. A library of guide RNAs was generated with single or multiple mismatches between guide sequences and target DNA. Based on these findings, target sites for SpCas9 can be selected based on the following guidelines.

[0168] To maximize SpCas9 specificity for editing a particular gene, target sites within the locus of interest should be selected such that potential "off-target" genomic sequences obey the following four constraints: first, they should not be followed by a PAM with either a 5'-NGG or NAG sequence. Second, their overall sequence similarity with the target sequence should be minimized. Third, the maximum number of mismatches should be present within the PAM-proximal region of the off-target site. Finally, the maximum number of mismatches should be contiguous or separated by less than four bases.

[0169] Similar methods can be used to evaluate the specificity of other Cas9 orthologs and establish criteria for the selection of specific target sites within the genome of a target species. As described above, phylogenetic analysis based on protein sequence conservation of this set revealed five families of Cas9, including three groups of large Cas9s (about 1400 amino acids) and two groups of small Cas9s (about 1100 amino acids) (see Figures 19 and 20A-F). Further details regarding Cas orthologs can be found in U.S. Patent Application Nos. 61 / 836,101 and 61 / 835,936 (Attorney Docket Nos. 44790.09.2022 and 4790.07.2022, respectively, and Broad References BI-2013 / 004E and BI-2013 / 004F), which are incorporated herein by reference.

[0170] Example 7: Engineering plants (microalgae) using Cas9 to target and manipulate plant genes Methods for delivering Cas9

[0171] Method 1: Applicants deliver Cas9 and guide RNA using a vector expressing Cas9 under the control of a constitutive promoter, e.g., Hsp70A-Rbc S2 or beta2-tubulin.

[0172] Method 2: We deliver Cas9 and T7 polymerase using vectors expressing Cas9 and T7 polymerase under the control of a constitutive promoter, e.g., Hsp70A-Rbc S2 or beta2-tubulin. Guide RNA is delivered using a vector containing a T7 promoter driving the guide RNA.

[0173] Method 3: We deliver Cas9 mRNA and in vitro transcribed guide RNA to algae cells. RNA can be transcribed in vitro. Cas9 mRNA consists of the coding region for Cas9 and the 3'UTR from Cop1 to ensure the stabilization of Cas9 mRNA.

[0174] For homologous recombination, applicants provide additional homology directed repair templates.

[0175] A cassette driving expression of Cas9 under the control of the beta-2 tubulin promoter, followed by sequence for the 3'UTR of Cop1. [ka] [ka] [ka]

[0176] A cassette driving expression of T7 polymerase under the control of the beta-2 tubulin promoter, followed by the sequence for the 3'UTR of Cop1: [ka] [ka]

[0177] Sequence of guide RNA driven by T7 promoter (T7 promoter, N represents targeting sequence): [ka]

[0178] Gene Delivery: Chlamydomonas reinhardtii strains CC-124 and CC-125 from the Chlamydomonas Resource Center are used for electroporation. The electroporation protocol follows the standard recommended protocol from the GeneArt Chlamydomonas Engineering kit.

[0179] We also generate a line of Chlamydomonas reinhardtii that constitutively expresses Cas9. This can be done by using pChlamy1 (linearized with PvuI) and selecting hygromycin-resistant colonies. The sequence for pChlamy1 containing Cas9 is shown below. In this approach to achieve gene knockout, it is only necessary to deliver RNA for the guide RNA. For homologous recombination, we deliver the guide RNA and linearized homologous recombination template.

[0180] pChlamy1-Cas9: [ka] [ka] [ka] [ka] [ka] [ka]

[0181] For all modified Chlamydomonas reinhardtii cells, Applicants confirmed successful modifications using PCR, SURVEYOR nuclease assay, and DNA sequencing.

[0182] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the present invention described herein can be used in the practice of the invention. The following claims define the scope of the invention, and it is intended that methods and structures within the scope of these claims and their equivalents be covered thereby.

[0183] References: 1. Urnov, FD, Rebar, EJ, Holmes, MC, Zhang, HS & Gregory, PD Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636-646 (2010). 2. Bogdanove, AJ & Voytas, DFTAL effectors: customizable proteins for DNA targeting. Science 333, 1843-1846 (2011). 3. Stoddard, BLHoming endonuclease structure and function.Q.Rev.Biophys.38,49-95(2005). 4.Bae, T. & Schneewind, O. Allelic replacement in Staphylococcus aureus with inducible counter-selection.Plasmid 55,58-63(2006). 5.Sung,C.K.,Li,H.,Claverys,J.P.&Morrison,D.A.An rpsL cassette,janus,for gene replacement through negative selection in Streptococcus pneumoniae.Appl.Environ.Microbiol.67,5190-5196(2001). 6.Sharan,S.K.,Thomason,L.C.,Kuznetsov,S.G.&Court,D.L.Recombineering:a homologous recombination-based method of genetic engineering.Nat.Protoc.4,206-223(2009). 7.Jinek,M.et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science 337,816-821(2012). 8.Deveau,H.,Garneau,J.E.&Moineau,S.CRISPR / Cas system and its role in phage-bacteria interactions.Annu.Rev.Microbiol.64,475-493(2010). 9.Horvath,P.&Barrangou,R.CRISPR / Cas,the immune system of bacteria and archaea.Science 327,167-170(2010). 10.Terns,M.P.&Terns,R.M.CRISPR-based adaptive immune systems.Curr.Opin.Microbiol.14,321-327(2011). 11.van der Oost,J.,Jore,M.M.,Westra,E.R.,Lundgren,M.&Brouns,S.J.CRISPR-based adaptive and heritable immunity in prokaryotes.Trends.Biochem.Sci.34,401-407(2009). 12.Brouns,S.J.et al.Small CRISPR RNAs guide antiviral defense in prokaryotes.Science 321,960-964(2008). 13.Carte,J.,Wang,R.,Li,H.,Terns,R.M.&Terns,M.P.Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes.Genes Dev.22,3489-3496(2008). 14.Deltcheva,E.et al.CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.Nature 471,602-607(2011). 15.Hatoum-Aslan,A.,Maniv,I.&Marraffini,L.A.Mature clustered,regularly interspaced,short palindromic repeats RNA(crRNA)length is measured by a ruler mechanism anchored at the precursor processing site.Proc.Natl.Acad.Sci.U.S.A.108,21218-21222(2011). 16.Haurwitz,R.E.,Jinek,M.,Wiedenheft,B.,Zhou,K.&Doudna,J.A.Sequence-and structure-specific RNA processing by a CRISPR endonuclease.Science 329,1355-1358(2010). 17.Deveau,H.et al.Phage response to CRISPR-encoded resistance in Streptococcus thermophilus.J.Bacteriol.190,1390-1400(2008). 18.Gasiunas,G.,Barrangou,R.,Horvath,P.&Siksnys,V.Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria.Proc.Natl.Acad.Sci.U.S.A.(2012). 19.Makarova,K.S.,Aravind,L.,Wolf,Y.I.&Koonin,E.V.Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems.Biol.Direct.6,38(2011). 20.Barrangou,R.RNA-mediated programmable DNA cleavage.Nat.Biotechnol.30,836-838(2012). 21.Brouns,S.J.Molecular biology.A Swiss army knife of immunity.Science 337,808-809(2012). 22.Carroll,D.A CRISPR Approach to Gene Targeting.Mol.Ther.20,1658-1660(2012). 23.Bikard,D.,Hatoum-Aslan,A.,Mucida,D.&Marraffini,L.A.CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection.Cell Host Microbe 12,177-186(2012). 24.Sapranauskas,R.et al.The Streptococcus thermophilus CRISPR / Cas system provides immunity in Escherichia coli.Nucleic Acids Res.(2011). 25.Semenova,E.et al.Interference by clustered regularly interspaced short palindromic repeat(CRISPR)RNA is governed by a seed sequence.Proc.Natl.Acad.Sci.U.S.A.(2011). 26.Wiedenheft,B.et al.RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions.Proc.Natl.Acad.Sci.U.S.A.(2011). 27.Zahner,D.&Hakenbeck,R.The Streptococcus pneumoniae beta-galactosidase is a surface protein.J.Bacteriol.182,5919-5921(2000). 28.Marraffini,L.A.,Dedent,A.C.&Schneewind,O.Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria.Microbiol.Mol.Biol.Rev.70,192-221(2006). 29.Motamedi,M.R.,Szigety,S.K.&Rosenberg,S.M.Double-strand-break repair recombination in Escherichia coli:physical evidence for a DNA replication mechanism in vivo.Genes Dev.13,2889-2903(1999). 30.Hosaka,T.et al.The novel mutation K87E in ribosomal protein S12 enhances protein synthesis activity during the late growth phase in Escherichia coli.Mol.Genet.Genomics 271,317-324(2004). 31.Costantino,N.&Court,D.L.Enhanced levels of lambda Red-mediated recombinants in mismatch repair mutants.Proc.Natl.Acad.Sci.U.S.A.100,15748-15753(2003). 32.Edgar,R.&Qimron,U.The Escherichia coli CRISPR system protects from lambda lysogenization,lysogens,and prophage induction.J.Bacteriol.192,6291-6294(2010). 33.Marraffini,L.A.&Sontheimer,E.J.Self versus non-self discrimination during CRISPR RNA-directed immunity.Nature 463,568-571(2010). 34.Fischer,S.et al.An archaeal immune system can detect multiple Protospacer Adjacent Motifs(PAMs)to target invader DNA.J.Biol.Chem.287,33351-33363(2012). 35.Gudbergsdottir,S.et al.Dynamic properties of the Sulfolobus CRISPR / Cas and CRISPR / Cmr systems when challenged with vector-borne viral and plasmid genes and protospacers.Mol.Microbiol.79,35-49(2011). 36.Wang,H.H.et al.Genome-scale promoter engineering by coselection MAGE.Nat Methods 9,591-593(2012). 37.Cong,L. et al.Multiplex Genome Engineering Using CRISPR / Cas Systems.Science In press(2013). 38.Mali,P.et al.RNA-Guided Human Genome Engineering via Cas9.Science In press(2013). 39.Hoskins,J.et al.Genome of the bacterium Streptococcus pneumoniae strain R6.J.Bacteriol.183,5709-5717(2001). 40.Havarstein,L.S.,Coomaraswamy,G.&Morrison,D.A.An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae.Proc.Natl.Acad.Sci.U.S.A.92,11140-11144(1995). 41.Horinouchi,S.&Weisblum,B.Nucleotide sequence and functional map of pC194,a plasmid that specifies inducible chloramphenicol resistance.J.Bacteriol.150,815-825(1982). 42.Horton,R.M.In Vitro Recombination and Mutagenesis of DNA:SOEing Together Tailor-Made Genes.Methods Mol.Biol.15,251-261(1993). 43.Podbielski,A.,Spellerberg,B.,Woischnik,M.,Pohl,B.&Lutticken,R.Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci(GAS).Gene 177,137-147(1996). 44.Husmann,L.K.,Scott,J.R.,Lindahl,G.&Stenberg,L.Expression of the Arp protein,a member of the M protein family,is not sufficient to inhibit phagocytosis of Streptococcus pyogenes.Infection and immunity 63,345-348(1995). 45. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6, 343 - 345 (2009). 46. Garneau J. E. et al. The CRISPR / Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67 - 71 (04 November 2010) 47. Barrangou R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007 Mar 23;315(5819):1709 - 12. 48. Ishino Y. et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987 Dec;169(12):5429 - 33. 49. Mojica F. J. M et al. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Molecular Microbiology(2000)36(1), 244 - 246. 50. Jansen R. et al. Identification of genes that are associated with DNA repeats in prokaryotes. Molecular Microbiology(2002)43(6), 1565 - 1575. [Sequence Listing] SEQUENCE LISTING <110> THE BROAD INSTITUTE, INC. MASSACHUSETTS INSTITUTE OF TECHNOLOGY <120> CRISPR-CAS SYSTEMS AND METHODS FOR ALTERING EXPRESSION OF GENE PRODUCTS <130> F67913D1 <140> JP 2019-035911 <141> 2019-02-28 <150> US 14 / 054,414 <151> 2013-10-15 <150> US 61 / 842,322 <151> 2013-07-02 <150> US 61 / 835,931 <151> 2013-06-17 <150> US 61 / 791,409 <151> 2013-03-15 <150> US 61 / 748,427 <151> 2013-01-02 <150> US 61 / 736,527 <151> 2012-12-12 <160> 181 <170> PatentIn version 3.5 <210> 1 <211> 27 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t or g <220> <221> modified_base <222> (21)..(22) <223> a, c, t, g, unknown or other <400> 1 nnnnnnnnnn nnnnnnnnnn nnagaaw 27 <210> 2 <211> 19 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(12) <223> a, c, t or g <220> <221> modified_base <222> (13)..(14) <223> a, c, t, g, unknown or other <400> 2 nnnnnnnnnn nnnnagaaw 19 <210> 3 <211> 27 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t or g <220> <221> modified_base <222> (21)..(22) <223> a, c, t, g, unknown or other <400> 3 nnnnnnnnnn nnnnnnnnnn nnagaaw 27 <210> 4 <211> 18 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(11) <223> a, c, t or g <220> <221> modified_base <222> (12)..(13) <223> a, c, t, g, unknown or other <400> 4 nnnnnnnnnn nnnagaaw 18 <210> 5 <211> 137 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 5 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcaagatt tagaaataaa tcttgcagaa 60 gctacaaaga taaggcttca tgccgaaatc aacaccctgt cattttatgg cagggtgttt 120 tcgttattta atttttt 137 <210> 6 <211> 123 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 6 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttcgt tatttaattt 120 ttt 123 <210> 7 <211> 110 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 7 nnnnnnnnnn nnnnnnnnnn gtttttgtac tctcagaaat gcagaagcta caaagataag 60 gcttcatgcc gaaatcaaca ccctgtcatt ttatggcagg gtgttttttt 110 <210> 8 <211> 102 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 8 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60 cgttatcaac ttgaaaaagt ggcaccgagt cggtgctttt tt 102 <210> 9 <211> 88 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 9 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60 cgttatcaac ttgaaaaagt gttttttt 88 <210> 10 <211> 76 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, t, g, unknown or other <400> 10 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaatagc aagttaaaat aaggctagtc 60 cgttatcatt tttttt 76 <210> 11 <211> 12 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 11 gttttagagc ta 12 <210> 12 <211> 31 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 12 tagcaagtta aaataaggct agtccgtttt t 31 <210> 13 <211> 12 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 13 guuuuagagc ua 12 <210> 14 <211> 33 <212> DNA <213> Homo sapiens <400> 14 ggacatcgat gtcacctcca atgactaggg tgg 33 <210> 15 <211> 33 <212> DNA <213> Homo sapiens <400> 15 cattggaggt gacatcgatg tcctccccat tgg 33 <210> 16 <211> 33 <212> DNA <213> Homo sapiens <400> 16 ggaagggcct gagtccgagc agaagaagaa ggg 33 <210> 17 <211> 33 <212> DNA <213> Homo sapiens <400> 17 ggtggcgaga ggggccgaga ttgggtgttc agg 33 <210> 18 <211> 33 <212> DNA <213> Homo sapiens <400> 18 atgcaggagg gtggcgagag gggccgagat tgg 33 <210> 19 <211> 4677 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <400> 19 tctttcttgc gctatgacac ttccagcaaa aggtagggcg ggctgcgaga cggcttcccg 60 gcgctgcatg caacaccgat gatgcttcga ccccccgaag ctccttcggg gctgcatggg 120 cgctccgatg ccgctccagg gcgagcgctg tttaaatagc caggcccccg attgcaaaga 180 cattatagcg agctaccaaa gccatattca aacacctaga tcactaccac ttctacacag 240 gccactcgag cttgtgatcg cactccgcta agggggcgcc tcttcctctt cgtttcagtc 300 acaacccgca aacatgtacc catacgatgt tccagattac gcttcgccga agaaaaagcg 360 caaggtcgaa gcgtccgaca agaagtacag catcggcctg gacatcggca ccaactctgt 420 gggctgggcc gtgatcaccg acgagtacaa ggtgcccagc aagaaattca aggtgctggg 480 caacaccgac cggcacagca tcaagaagaa cctgatcgga gccctgctgt tcgacagcgg 540 cgaaacagcc gaggccaccc ggctgaagag aaccgccaga agaagataca ccagacggaa 600 gaaccggatc tgctatctgc aagagatctt cagcaacgag atggccaagg tggacgacag 660 cttcttccac agactggaag agtccttcct ggtggaagag gataagaagc acgagcggca 720 ccccatcttc ggcaacatcg tggacgaggt ggcctaccac gagaagtacc ccaccatcta 780 ccacctgaga aagaaactgg tggacagcac cgacaaggcc gacctgcggc tgatctatct 840 ggccctggcc cacatgatca agttccgggg ccacttcctg atcgagggcg acctgaaccc 900 cgacaacagc gacgtggaca agctgttcat ccagctggtg cagacctaca accagctgtt 960 cgaggaaaac cccatcaacg ccagcggcgt ggacgccaag gccatcctgt ctgccagact 1020 gagcaagagc agacggctgg aaaatctgat cgcccagctg cccggcgaga agaagaatgg 1080 cctgttcggc aacctgattg ccctgagcct gggcctgacc cccaacttca agagcaactt 1140 cgacctggcc gaggatgcca aactgcagct gagcaaggac acctacgacg acgacctgga 1200 caacctgctg gcccagatcg gcgaccagta cgccgacctg tttctggccg ccaagaacct 1260 gtccgacgcc atcctgctga gcgacatcct gagagtgaac accgagatca ccaaggcccc 1320 cctgagcgcc tctatgatca agagatacga cgagcaccac caggacctga ccctgctgaa 1380 agctctcgtg cggcagcagc tgcctgagaa gtacaaagag attttcttcg accagagcaa 1440 gaacggctac gccggctaca ttgacggcgg agccagccag gaagagttct acaagttcat 1500 caagcccatc ctggaaaaga tggacggcac cgaggaactg ctcgtgaagc tgaacagaga 1560 ggacctgctg cggaagcagc ggaccttcga caacggcagc atcccccacc agatccacct 1620 gggagagctg cacgccattc tgcggcggca ggaagatttt tacccattcc tgaaggacaa 1680 ccgggaaaag atcgagaaga tcctgacctt ccgcatcccc tactacgtgg gccctctggc 1740 caggggaaac agcagattcg cctggatgac cagaaagagc gaggaaacca tcaccccctg 1800 gaacttcgag gaagtggtgg acaagggcgc ttccgcccag agcttcatcg agcggatgac 1860 caacttcgat aagaacctgc ccaacgagaa ggtgctgccc aagcacagcc tgctgtacga 1920 gtacttcacc gtgtataacg agctgaccaa agtgaaatac gtgaccgagg gaatgagaaa 1980 gcccgccttc ctgagcggcg agcagaaaaa ggccatcgtg gacctgctgt tcaagaccaa 2040 ccggaaagtg accgtgaagc agctgaaaga ggactacttc aagaaaatcg agtgcttcga 2100 ctccgtggaa atctccggcg tggaagatcg gttcaacgcc tccctgggca cataccacga 2160 tctgctgaaa attatcaagg acaaggactt cctggacaat gaggaaaacg aggacattct 2220 ggaagatatc gtgctgaccc tgacactgtt tgaggacaga gagatgatcg aggaacggct 2280 gaaaacctat gcccacctgt tcgacgacaa agtgatgaag cagctgaagc ggcggagata 2340 caccggctgg ggcaggctga gccggaagct gatcaacggc atccgggaca agcagtccgg 2400 caagacaatc ctggatttcc tgaagtccga cggcttcgcc aacagaaact tcatgcagct 2460 gatccacgac gacagcctga cctttaaaga ggacatccag aaagcccagg tgtccggcca 2520 gggcgatagc ctgcacgagc acattgccaa tctggccggc agccccgcca ttaagaaggg 2580 catcctgcag acagtgaagg tggtggacga gctcgtgaaa gtgatgggcc ggcacaagcc 2640 cgagaacatc gtgatcgaaa tggccagaga gaaccagacc acccagaagg gacagaagaa 2700 cagccgcgag agaatgaagc ggatcgaaga gggcatcaaa gaggctgggca gccagatcct 2760 gaagaacac cccgtggaaa acacccagct ggaaacgag aagctcttacc tgtactacct 2820 gcagaatggg cgggatatgt acgtggacca ggaatggac atcaaccggc tgtccgacta 2880 cgatgtggac catatcgtgc ctcagagctt tctgaaggac gactccatcg acaacaaggt 2940 gctgaccaga agcgacaaga accggggcaa gagcgacaac gtgccctccg aagaggtcgt 3000 gaagagatg aagaactact ggcggcagct gctgaacgcc aagctgatta cccagagaaa 3060 gttcgacaat ctgaccaagg ccgagagagg cggcctgagc gaactggata aggccggctt 3120 3180 ctcccggatg aacactaagt acgacgagaa tgacaagctg atccgggag tgaagtgat 3240 caccctgaag tccaagctgg tgtccgattt ccgaagtt ttccagttt acaaagtgcg 3300 cgagatcaac aactaccacc acgcccacga cgcctacctg aacgccgtcg tgggaccgc 3360 cctgatcaaa aagtacccta agctggaag cgagttcgtg tacggcgact acaagtgta 3420 cgacgtgcgg aagatgatcg ccaagagcga gcaggaatc ggcaggcta ccgccaagta 3480 cttcttctac agcacatca tgaacttt tt CAGAccgag attaccctgg ccaacggcga 3540 gatccggaag cggcctctga tcgagacaa cggcgaacc ggggagatcg tgtggtaa 3600 gggccgggat ttgccaccg tgcggaagt gctgagcatg cccaagtga atatcgtgaa 3660 aaagaccgag gtgcagacag gcggctcag aaagagtct atcctgccca agaggaacag 3720 cgataagctg atcgccagaa agaggactg ggacctaag aagtacggcg gcttcgacag 3780 ccccaccgtg gcctattctg tgctggtggt ggccaaagtg gaaaagggca agtccaagaa 3840 actgaagagt gtgaaagagc tgctggggat caccatcatg gaaagaagca gcttcgagaa 3900 gaatcccatc gactttctgg aagccaaggg ctacaaagaa gtgaaaaagg acctgatcat 3960 caagctgcct aagtactccc tgttcgagct ggaaaacggc cggaagagaa tgctggcctc 4020 tgccggcgaa ctgcagaagg gaaacgaact ggccctgccc tccaaatatg tgaacttcct 4080 gtacctggcc agccactatg agaagctgaa gggctccccc gaggataatg agcagaaaca 4140 gctgtttgtg gaacagcaca agcactacct ggacgagatc atcgagcaga tcagcgagtt 4200 ctccaagaga gtgatcctgg ccgacgctaa tctggacaaa gtgctgtccg cctacaacaa 4260 gcaccgggat aagcccatca gagagcaggc cgagaatatc atccacctgt ttaccctgac 4320 caatctggga gcccctgccg ccttcaagta ctttgacacc accatcgacc ggaagaggta 4380 caccagcacc aaagaggtgc tggacgccac cctgatccac cagagcatca ccggcctgta 4440 cgagacacgg atcgacctgt ctcagctggg aggcgacagc cccaagaaga agagaaaggt 4500 ggaggccagc taaggatccg gcaagactgg ccccgcttgg caacgcaaca gtgagcccct 4560 ccctagtgtg tttggggatg tgactatgta ttcgtgtgtt ggccaacggg tcaacccgaa 4620 cagattgata cccgccttgg catttcctgt cagaatgtaa cgtcagttga tggtact 4677 <210> 20 <211> 3150 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <400> 20 tctttcttgc gctatgacac ttccagcaaa aggtagggcg ggctgcgaga cggcttcccg 60 gcgctgcatg caacaccgat gatgcttcga ccccccgaag ctccttcggg gctgcatggg 120 cgctccgatg ccgctccagg gcgagcgctg tttaaatagc caggcccccg attgcaaaga 180 cattatagcg agctaccaaa gccatattca aacacctaga tcactaccac ttctacacag 240 gccactcgag cttgtgatcg cactccgcta aggggcgcc tcttctctctt cgtttcagtc 300 acaacccgca aacatgccta agaagaagag gaaggttaac acgattaaca tcgctaagaa 360 cgacttctct gacatcgaac tggctgctat cccgttcaac actctggctg accattacgg 420 tgagcgttta gctcgcgaac agttggccct tgagcatgag tcttacgaga tgggtgaagc 480 acgcttcgc aagatgtttg agcgtcaact taaagctggt gaggttgcgg ataacgctgc 540 cgccaagcct ctcatcacta ccctactccc taagatgatt gcagcatca akgactggtt 600 tgaggaagtg aaagctaagc gcggcaagcg cccgacagcc ttccagttcc tgcaagaaat 660 caagccggaa gccgtagcgt acatcaccat taagaccact ctggcttgcc taaccagtgc 720 tgacaataca accgttcagg ctgtagcaag cgcaatcggt cgggccattg aggacgaggc 780 tcgcttcggt cgtatccgtg accttgaagc tagcacttc aagaaaaacg ttgaggaaca actcaacaag cgcgtagggc actcaacaa gaaagcattt atgcaagttg tcgaggctga catgctctct aagggtctc tcggtggcga ggcgtggtct tcgtggcata aggaagactc 960 tattcatgta ggagtacgct gcatcgagat gctcattgag tcaaccgga tggttagctt acaccgccaa aatgctggcg tagtagtca agactctgag actatcgaac tcgcacctga atacgctgag gctatcgcaa cccgtgcagg tgcgctggct ggcatctctc cgatgttcca accttgcgta gttcctccta agccgtggac tggcattact ggtggtggct attgggctaa cggtcgtcgt cctctggcgc tggtgcgtac tcacagtaag aaagcactga tgcgctacga agacgtttac atgcctgagg tgtacaaagc gattaacatt gcgcaaaaca ccgcatgga aatcaacaag aaagtcctag cggtcgccaa cgtaatcacc aagtggaagc attgtccggt 1380 cgaggacatc cctgcgattg agcgtgaaga actcccgatg aaaccggaag acatcgacat 1440 gaatcctgag gctctcaccg cgtggaaacg tgctgccgct gctgtgtacc gcaaggacaa 1500 ggctcgcaag tctcgccgta tcagccttga gttcatgctt gagcaagcca ataagtttgc 1560 taaccataag gccatctggt tcccttacaa catggactgg cgcggtcgtg tttacgctgt 1620 gtcaatgttc aacccgcaag gtaacgatat gaccaaagga ctgcttacgc tggcgaaagg 1680 taaaccaatc ggtaaggaag gttactactg gctgaaaatc cacggtgcaa actgtgcggg 1740 tgtcgacaag gttccgttcc ctgagcgcat caagttcatt gaggaaaacc acgagaacat 1800 catggcttgc gctaagtctc cactggagaa cacttggtgg gctgagcaag attctccgtt 1860 ctgcttcctt gcgttctgct ttgagtacgc tggggtacag caccacggcc tgagctataa 1920 ctgctccctt ccgctggcgt ttgacgggtc ttgctctggc atccagcact tctccgcgat 1980 gctccgagat gaggtaggtg gtcgcgcggt taacttgctt cctagtgaaa ccgttcagga 2040 catctacggg attgttgcta agaaagtcaa cgagattcta caagcagacg caatcaatgg 2100 gaccgataac gaagtagtta ccgtgaccga tgagaacact ggtgaaatct ctgagaaagt 2160 caagctgggc actaaggcac tggctggtca atggctggct tacggtgtta ctcgcagtgt 2220 gactaagcgt tcagtcatga cgctggctta cgggtccaaa gagttcggct tccgtcaaca 2280 agtgctggaa gataccattc agccagctat tgattccggc aagggtctga tgttcactca 2340 gccgaatcag gctgctggat acatggctaa gctgatttgg gaatctgtga gcgtgacggt 2400 ggtagctgcg gttgaagcaa tgaactggct taagtctgct gctaagctgc tggctgctga 2460 ggtcaaagat aagaagactg gagagattct tcgcaagcgt tgcgctgtgc attgggtaac 2520 tcctgatggt ttccctgtgt ggcaggaata caagaagcct attcagacgc gcttgaacct 2580 gatgttcctc ggtcagttcc gcttacagcc taccattaac accaacaaag atagcgagat 2640 tgatgcacac aaacaggagt ctggtatcgc tcctaacttt gtacacagcc aagacggtag 2700 ccaccttcgt aagactgtag tgtgggcaca cgagaagtac ggaatcgaat cttttgcact 2760 gattcacgac tccttcggta cgattccggc tgacgctgcg aacctgttca aagcagtgcg 2820 cgaaactatg gttgacacat atgagtcttg tgatgtactg gctgatttct acgaccagtt 2880 cgctgaccag ttgcacgagt ctcaattgga caaaatgcca gcacttccgg ctaaaggtaa 2940 cttgaacctc cgtgacatct tagagtcgga cttcgcgttc gcgtaaggat ccggcaagac 3000 tggccccgct tggcaacgca acagtgagcc cctccctagt gtgtttgggg atgtgactat 3060 gtattcgtgt gttggccaac gggtcaaccc gaacagattg atacccgcct tggcatttcc 3120 tgtcagaatg taacgtcagt tgatggtact 3150 <210> 21 <211> 125 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <220> <221> modified_base <222> (23)..(42) <223> a, c, t, g, unknown or other <400> 21 gaaattaata cgactcacta tannnnnnnn nnnnnnnnnn nngttttaga gctagaaata 60 gcaagttaaa ataaggctag tccgttatca acttgaaaaa gtggcaccga gtcggtgctt 120 ttttt 125 <210> 22 <211> 8452 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <400> 22 tgcggtattt cacaccgcat caggtggcac ttttcgggga aatgtgcgcg gaacccctat 60 ttgtttattt ttctaaatac attcaaatat gtatccgctc atgagattat caaaaaggat 120 cttcacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa gtatatatga 180 gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg 240 tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta cgatacggga 300 gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct caccggctcc 360 agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg gtcctgcaac 420 tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc 480 agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc 540 gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta catgatcccc 600 catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc 720 atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct gagaatagtg tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag cagaacttta aaagtgctca tcattggaa acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact gatcttcagc 960 atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt attgtctcat gaccaaaatc ccttaacgtg agttttcgtt ccactgagcg tcagaccccg tagaaagat caaaggatct tcttgagatc ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta ccagcggtgg tttgtttgcc 1260 ggatcaagag ctaccaactc tttttccgaa ggtaactggc ttcagcagag cgcagatacc 1320 aaatactgtt cttctagtgt agccgtagtt aggccaccac ttcaagaact ctgtagcacc 1380 gcctacatac ctcgctctgc taatcctgtt accagtggct gttgccagtg gcgataagtc 1440 gtgtcttacc gggttggact caagacgata gttaccggat aaggcgcagc ggtcgggctg 1500 aacggggggt tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata 1560 cctacagcgt gagctatgag aaagcgccac gcttcccgaa gggagaaagg cggacaggta 1620 tccggtaagc ggcagggtcg gaacaggaga gcgcacgagg gagcttccag ggggaaacgc 1680 ctggtatctt tatagtcctg tcgggtttcg ccacctctga cttgagcgtc gatttttgtg 1740 atgctcgtca ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacggtt 1800 cctggccttt tgctggcctt ttgctcacat gttctttcct gcgttatccc ctgattctgt 1860. ggataaccgt attaccgcct ttgagtgagc tgataccgct cgccgcagcc gaacgaccga gcgcagcgag tcagtgagcg aggaagcggt cgctgaggct tgacatgatt ggtgcgtatg tttgtatgaa gctacaggac tgatttggcg ggctatgagg gcgggggaag ctctggaagg gccgcgatgg ggcgcgcggc gtccagaagg cgccatacgg cccgctggcg gcacccatcc 2100 ggtataaaag cccgcgaccc cgaacggtga cctccacttt cagcgacaaa cgagcactta 2220. actattctgc cgctatacat aaccactcag ctagcttaag atcccatcaa gcttgcatgc cgggcgcgcc agaaggagcg cagccaaacc aggatgatgt ttgatggggt 2280. atttgagcac ttgcaaccct tatccggag ccccctggcc cacaaaggct aggcgccat gcaagcagtt cgcatgcagc ccctggagcg gtgccctcct gataaccgg ccagggggcc tatgttcttt acttttttac aagagaagtc actcaacatc ttaaaatggc caggtgagtc 2460 gacgagcaag cccggcggat caggcagcgt gcttgcagat ttgacttgca acgcccgcat 2520 tgtgtcgacg aaggcttttg gctcctctgt cgctgtctca agcagcatct aaccctgcgt 2580 cgccgtttcc atttgcagga gattcgaggt accatgtacc catacgatgt tccagattac 2640 gcttcgccga agaaaaagcg caaggtcgaa gcgtccgaca agaagtacag catcggcctg 2700 gacatcggca ccaactctgt gggctgggcc gtgatcaccg acgagtacaa ggtgcccagc 2760 aagaaattca aggtgctggg caacaccgac cggcacagca tcaagaagaa cctgatcgga 2820 gccctgctgt tcgacagcgg cgaaacagcc gaggccaccc ggctgaagag aaccgccaga 2880 agaagataca ccagacggaa gaaccggatc tgctatctgc aagagatctt cagcaacgag 2940 atggccaagg tggacgacag cttcttccac agactggaag agtccttcct ggtggaagag 3000 gataagaagc acgagcggca ccccatcttc ggcaacatcg tggacgaggt ggcctaccac 3060 gagaagtacc ccaccatcta ccacctgaga aagaaactgg tggacagcac cgacaaggcc 3120 gacctgcggc tgatctatct ggccctggcc cacatgatca agttccgggg ccacttcctg 3180 atcgagggcg acctgaaccc cgacaacagc gacgtggaca agctgttcat ccagctggtg 3240 cagacctaca accagctgtt cgaggaaaac cccatcaacg ccagcggcgt ggacgccaag 3300 gccatcctgt ctgccagact gagcaagagc agacggctgg aaaatctgat cgcccagctg 3360 cccggcgaga agaagaatgg cctgttcggc aacctgattg ccctgagcct gggcctgacc 3420 cccaacttca agagcaactt cgacctggcc gaggatgcca aactgcagct gagcaaggac 3480 acctacgacg acgacctgga caacctgctg gcccagatcg gcgaccagta cgccgacctg 3540 tttctggccg ccaagaacct gtccgacgcc atcctgctga gcgacatcct gagagtgaac 3600 accgagatca ccaaggcccc cctgagcgcc tctatgatca agagatacga cgagcaccac 3660 caggacctga ccctgctgaa agctctcgtg cggcagcagc tgcctgagaa gtacaaagag 3720 attttcttcg accagagcaa gaacggctac gccggctaca ttgacggcgg agccagccag 3780 gaagagttct acaagttcat caagcccatc ctggaaaaga tggacggcac cgaggaactg 3840 ctcgtgaagc tgaacagaga ggacctgctg cggaagcagc ggaccttcga caacggcagc 3900 atcccccacc agatccacct gggagagctg cacgccattc tgcggcggca ggaagatttt 3960 tacccattcc tgaaggacaa ccgggaaaag atcgagaaga tcctgacctt ccgcatcccc 4020 tactacgtgg gccctctggc caggggaaac agcagattcg cctggatgac cagaaagagc 4080 gaggaaacca tcaccccctg gaacttcgag gaagtggtgg acaagggcgc ttccgcccag 4140 agcttcatcg agcggatgac caacttcgat aagaacctgc ccaacgagaa ggtgctgccc 4200 aagcacagcc tgctgtacga gtacttcacc gtgtataacg agctgaccaa agtgaaatac 4260 gtgaccgagg gaatgagaaa gcccgccttc ctgagcggcg agcagaaaaa ggccatcgtg 4320 gacctgctgt tcaagaccaa ccggaaagtg accgtgaagc agctgaaaga ggactacttc 4380 aagaaaatcg agtgcttcga ctccgtggaa atctccggcg tggaagatcg gttcaacgcc 4440 tccctgggca cataccacga tctgctgaaa attatcaagg acaaggactt cctggacaat 4500 gaggaaaacg aggacattct ggaagatatc gtgctgaccc tgacactgtt tgaggacaga 4560 gagatgatcg aggaacggct gaaaacctat gcccacctgt tcgacgacaa agtgatgaag 4620 cagctgaagc ggcggagata caccggctgg ggcaggctga gccggaagct gatcaacggc 4680 atccgggaca agcagtccgg caagacaatc ctggatttcc tgaagtccga cggcttcgcc 4740 aacagaaact tcatgcagct gatccacgac gacagcctga cctttaaaga ggacatccag 4800 aaagcccagg tgtccggcca gggcgatagc ctgcacgagc acattgccaa tctggccggc 4860 agccccgcca ttaagaaggg catcctgcag acagtgaagg tggtggacga gctcgtgaaa 4920 gtgatgggcc ggcacaagcc cgagaacatc gtgatcgaaa tggccagaga gaaccagacc 4980 acccagaagg gacagaagaa cagccgcgag agaatgaagc ggatcgaaga gggcatcaaa 5040 gagctggggca gccagatcct gaagaacac cccgtggaaa acacccagct gcagaacgag 5100 aagctgtacc tgtactacct gcagaatggg cgggatatgt acgtggacca ggaactggac 5160 atcaaccggc tgtccgacta cgatgtggac catatcgtgc ctcagagctt tctgaaggac 5220 gactccatcg acaacaaggt gctgaccaga agcgacaaga accggggcaa gagcgacaac 5280 gtgccctccg aagaggtcgt gaagaagatg aagaactact ggcggcagct gctgaacgcc 5340 aagctgatta cccagagaaa gttcgacaat ctgaccaagg ccgagagagg cggcctgagc 5400 gaactggata aggccggctt catcaagaga cagctggtgg aaacccggca gatcacaaag 5460 cacgtggcac agatcctgga ctcccggatg aacactaagt acgacgagaa tgacaagctg 5520 atccgggaag tgaaagtgat caccctgaag tccaagctgg tgtccgattt ccggaaggat 5580 ttccagtttt acaaagtgcg cgagatcaac aactaccacc acgcccacga cgcctacctg 5640 aacgccgtcg tgggaaccgc cctgatcaaa aagtacccta agctggaaag cgagttcgtg 5700 tacggcgact acaaggtgta cgacgtgcgg aagatgatcg ccaagagcga gcaggaaatc 5760 ggcaaggcta ccgccaagta cttcttctac agcaacatca tgaacttttt caagaccgag 5820 attaccctgg ccaacggcga gatccggaag cggcctctga tcgagacaaa cggcgaaacc 5880 ggggagatcg tgtgggataa gggccgggat tttgccaccg tgcggaaagt gctgagcatg 5940 ccccaagtga atatcgtgaa aaagaccgag gtgcagacag gcggcttcag caaagagtct 6000 atcctgccca agaggaacag cgataagctg atcgccagaa agaaggactg ggaccctaag 6060 aagtacggcg gcttcgacag ccccaccgtg gcctattctg tgctggtggt ggccaaagtg 6120 gaaaagggca agtccaagaa actgaagagt gtgaaagagc tgctggggat caccatcatg 6180 gaaagaagca gcttcgagaa gaatcccatc gactttctgg aagccaaggg ctacaaagaa 6240 gtgaaaaagg acctgatcat caagctgcct aagtactccc tgttcgagct ggaaaacggc 6300 cggaagagaa tgctggcctc tgccggcgaa ctgcagaagg gaaacgaact ggccctgccc 6360 tccaaatatg tgaacttcct gtacctggcc agccactatg agaagctgaa gggctccccc 6420 gaggataatg agcagaaaca gctgtttgtg gaacagcaca agcactacct ggacgagatc 6480 atcgagcaga tcagcgagtt ctccaagaga gtgatcctgg ccgacgctaa tctggacaaa 6540 gtgctgtccg cctacaacaa gcaccgggat aagcccatca gagagcaggc cgagaatatc 6600 atccacctgt ttaccctgac caatctggga gcccctgccg ccttcaagta ctttgacacc 6660 accatcgacc ggaagaggta caccagcacc aaagaggtgc tggacgccac cctgatccac 6720 cagagcatca ccggcctgta cgagacacgg atcgacctgt ctcagctgggg aggcgacagc 6780 cccaagaaga agaaaggt ggaggccagc taacatatga ttcgaatgtc tttcttgcgc 6840 tatgacactt ccagcaaaag gtagggcggg ctgcgagacg gcttccccggc gctgcatgca 6900 acaccgatga tgcttcgacc ccccgaagct ccttcggggc tgcatgggcg ctccgatgcc 6960 gctccagggc gagcgctggt taaatagcca ggccccccgat tgcaaagaca ttatagcgag 7020 ctaccaaagc catattcaaa cacctagatc actaccactt ctacacaggc cactcgagct 7080 tgtgatcgca ctccgctaag ggggcgcctc ttcctcttcg tttcagtcac aacccgcaaa 7140 catgacacaa gaatccctgt tactttcga ccgtattgat tcggatgatt cctacgcgag 7200 cctgcggaac gaccaggaat tctgggaggt gagtcgacga gcaagcccgg cggatcaggc 7260 agcgtgcttg cagatttgac ttgcaacgcc cgcattgtgt cgacgaaggc ttttggctcc 7320 tctgtcgctg tctcaagcag catctaaccc tgcgtcgccg tttccatttg cagccgctgg 7380 cccgccgagc cctggaggag ctcgggctgc cggtgccgcc ggtgctgcgg gtgcccggcg 7440 agagcaccaa ccccgtactg gtcggcgagc ccggcccggt gatcaagctg ttcggcgagc 7500 actggtgcgg tccggagagc ctcgcgtcgg agtcggaggc gtacgcggtc ctggcggacg 7560 ccccggtgcc ggtgccccgc ctcctcggcc gcggcgagct gcggcccggc accggagcct 7620 ggccgtggcc ctacctggtg atgagccgga tgaccggcac cacctggcgg tccgcgatgg 7680 acggcacgac cgaccggaac gcgctgctcg ccctggcccg cgaactcggc cgggtgctcg 7740 gccggctgca cagggtgccg ctgaccggga acaccgtgct caccccccat tccgaggtct 7800 tcccggaact gctgcgggaa cgccgcgcgg cgaccgtcga ggaccaccgc gggtggggct 7860 acctctcgcc ccggctgctg gaccgcctgg aggactggct gccggacgtg gacacgctgc 7920 tggccggccg cgaaccccgg ttcgtccacg gcgacctgca cgggaccaac atcttcgtgg 7980 acctggccgc gaccgaggtc accgggatcg tcgacttcac cgacgtctat gcgggagact 8040 cccgctacag cctggtgcaa ctgcatctca acgccttccg gggcgaccgc gagatcctgg 8100 ccgcgctgct cgacggggcg cagtggaagc ggaccgagga cttcgcccgc gaactgctcg 8160 ccttcacctt cctgcacgac ttcgaggtgt tcgaggagac cccgctggat ctctccggct 8220 tcaccgatcc ggaggaactg gcgcagttcc tctgggggcc gccggacacc gcccccggcg 8280 cctgataagg atccggcaag actggccccg cttggcaacg caacagtgag cccctcccta 8340 gtgtgtttgg ggatgtgact atgtattcgt gtgttggcca acgggtcaac ccgaacagat 8400 tgatacccgc cttggcattt cctgtcagaa tgtaacgtca gttgatggta ct 8452 <210> 23 <211> 102 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <400> 23 gttttagagc tatgctgttt tgaatggtcc caaaacggaa gggcctgagt ccgagcagaa 60 gaagaagttt tagagctatg ctgttttgaa tggtcccaaa ac 102 <210> 24 <211> 100 <212> DNA <213> Homo sapiens <400> 24 cggaggacaa agtacaaacg gcagaagctg gaggaggaag ggcctgagtc cgagcagaag 60 aagaagggct cccatcacat caaccggtgg cgcattgcca 100 <210> 25 <211> 50 <212> DNA <213> Homo sapiens <400> 25 agctggagga ggaagggcct gagtccgagc agaagaagaa gggctcccac 50 <210> 26 <211> 30 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 26 gaguccgagc agaagaagaa guuuuagagc 30 <210> 27 <211> 49 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 27 agctggagga ggaagggcct gagtccgagc agaagagaag ggctcccat 49 <210> 28 <211> 53 <212> DNA <213> Homo sapiens <400> 28 ctggaggagg aagggcctga gtccgagcag aagaagaagg gctcccatca cat 53 <210> 29 <211> 52 <212> DNA <213> Homo sapiens <400> 29 ctggaggagg aagggcctga gtccgagcag aagagaaggg ctcccatcac at 52 <210> 30 <211> 54 <212> DNA <213> Homo sapiens <400> 30 ctggaggagg aagggcctga gtccgagcag aagaaagaag ggctcccatc acat 54 <210> 31 <211> 50 <212> DNA <213> Homo sapiens <400> 31 ctggaggagg aagggcctga gtccgagcag aagaagggct cccatcacat 50 <210> 32 <211> 47 <212> DNA <213> Homo sapiens <400> 32 ctggaggagg aagggcctga gccgagcag aagggctccc atcacat 47 <210> 33 <211> 48 <212> DNA <213> Homo sapiens <400> 33 ctggaggagg aagggcctga gtccgagcag aagaagaagg gctcccat 48 <210> 34 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 34 gaguccgagc agaagaagau 20 <210> 35 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 35 gaguccgagc agaagaagua 20 <210> 36 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 36 gaguccgagc agaagaacaa 20 <210> 37 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 37 gaguccgagc agaagaugaa 20 <210> 38 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 38 gaguccgagc agaaguagaa 20 <210> 39 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 39 gaguccgagc agaugaagaa 20 <210> 40 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 40 gaguccgagc acaagaagaa 20 <210> 41 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 41 gaguccgagg agaagaagaa 20 <210> 42 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 42 gaguccgugc agaagaagaa 20 <210> 43 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 43 gagucggagc agaagaagaa 20 <210> 44 <211> 20 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 44 gagaccgagc agaagaagaa 20 <210> 45 <211> 24 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 45 aatgacaagc ttgctagcgg tggg 24 <210> 46 <211> 39 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 46 aaaacggaag ggcctgagtc cgagcagaag aagaagttt 39 <210> 47 <211> 39 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 47 aaacaggggc cgagattggg tgttcagggc agaggtttt 39 <210> 48 <211> 38 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 48 aaaacggaag ggcctgagtc cgagcagaag aagaagtt 38 <210> 49 <211> 40 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 49 aacggaggga ggggcacaga tgagaaactc agggttttag 40 <210> 50 <211> 38 <212> DNA <213> Homo sapiens <400> 50 agcccttctt cttctgctcg gactcaggcc cttcctcc 38 <210> 51 <211> 40 <212> DNA <213> Homo sapiens <400> 51 cagggaggga ggggcacaga tgagaaactc aggaggcccc 40 <210> 52 <211> 80 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 52 ggcaatgcgc caccggttga tgtgatggga gcccttctag gaggccccca gagcagccac 60 tggggcctca acactcaggc 80 <210> 53 <211> 33 <212> DNA <213> Homo sapiens <400> 53 catcgatgtc ctccccattg gcctgcttcg tgg 33 <210> 54 <211> 33 <212> DNA <213> Homo sapiens <400> 54 ttcgtggcaa tgcgccaccg gttgatgtga tgg 33 <210> 55 <211> 33 <212> DNA <213> Homo sapiens <400> 55 tcgtggcaat gcgccaccgg ttgatgtgat ggg 33 <210> 56 <211> 33 <212> DNA <213> Homo sapiens <400> 56 tccagcttct gccgtttgta ctttgtccctc cgg 33 <210> 57 <211> 33 <212> DNA <213> Homo sapiens <400> 57 ggagggggg gcacagatga gaaactcagg agg 33 <210> 58 <211> 33 <212> DNA <213> Homo sapiens <400> 58 aggggccgag attgggtgtt aggggcag agg 33 <210> 59 <211> 33 <212> DNA <213> Muscles <400> 59 caagcactga gtgccattag ctaatgcat agg 33 <210> 60 <211> 33 <212> DNA <213> Muscles <400> 60 aatgcatagg gtaccacca caggtgccag ggg 33 <210> 61 <211> 33 <212> DNA <213> Muscles <400> 61 acacacatgg gaagccctct gggccaggaa agg 33 <210> 62 <211> 37 <212> DNA <213> Homo sapiens <400> 62 ggaggaggta gtatacagaa acacagaa gtagaat 37 <210> 63 <211> 37 <212> DNA <213> Homo sapiens <400> 63 agaatgtaga ggagtcacag aaactcagca ctagaaa 37 <210> 64 <211> 98 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 64 ggacgaaaca ccggaaccat tcaaaacagc atagcaagtt aaaataaggc tagtccgtta 60 tcaacttgaa aaagtggcac cgagtcggtg cttttttt 98 <210> 65 <211> 186 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic polynucleotide" <400> 65 ggacgaaaca ccggtagtat taagtattgt tttatggctg ataaatttct ttgaatttct 60 ccttgattat ttgttataaa agttataaaa taatcttgtt ggaaccattc aaaacagcat 120 agcaagttaa aataaggcta gtccgttatc aacttgaaaa agtggcaccg agtcggtgct 180 tttttt 186 <210> 66 <211> 95 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 66 gggttttaga gctatgctgt tttgaatggt cccaaaacgg gtcttcgaga agacgtttta 60 gagctatgct gttttgaatg gtcccaaaac ttttt 95 <210> 67 <211> 36 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (5)..(34) <223> a, c, t, g, unknown or other <400> 67 aaacnnnnnn nnnnnnnnnn nnnnnnnnnn nnnngt 36 <210> 68 <211> 36 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (7)..(36) <223> a, c, t, g, unknown or other <400> 68 taaaacnnnn nnnnnnnnnn nnnnnnnnnn nnnnnn 36 <210> 69 <211> 84 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 69 gtggaaagga cgaaacaccg ggtcttcgag aagacctgtt ttagagctag aaatagcaag 60 ttaaaataag gctagtccgt tttt 84 <210> 70 <211> 24 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (6)..(24) <223> a, c, t, g, unknown or other <400> 70 caccgnnnnn nnnnnnnnnn nnnn 24 <210> 71 <211> 24 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (5)..(23) <223> a, c, t, g, unknown or other <400> 71 aaacnnnnnn nnnnnnnnnn nnnc 24 <210> 72 <211> 46 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(19) <223> a, c, u, g, unknown or other <400> 72 nnnnnnnnnn nnnnnnnnng uuauuguacu cucaagauuu auuuuu 46 <210> 73 <211> 91 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 73 guuacuuaaa ucuugcagaa gcuacaaaga uaaggcuuca ugccgaaauc aacacccugu 60 cauuuuaugg caggguguuu ucguuauuua a 91 <210> 74 <211> 70 <212> DNA <213> Homo sapiens <400> 74 ttttctagtg ctgagtttct gtgactcctc tacattctac ttctctgtgt ttctgtatac 60 tacctcctcc 70 <210> 75 <211> 122 <212> DNA <213> Homo sapiens <400> 75 ggaggaaggg cctgagtccg agcagaagaa gaagggctcc catcacatca accggtggcg 60 cattgccacg aagcaggcca atggggagga catcgatgtc acctccaatg actagggtgg 120 gc 122 <210> 76 <211> 48 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (3)..(32) <223> a, c, u, g, unknown or other <400> 76 acnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnguuuuaga gcuaugcu 48 <210> 77 <211> 67 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> source <223> / note="Description of Combined DNA / RNA Molecule: Synthetic oligonucleotide" <400> 77 agcauagcaa guuaaaauaa ggctaguccg uuaucaacuu gaaaaagugg caccgagucg 60 gugcuuu 67 <210> 78 <211> 62 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <400> 78 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60 cg 62 <210> 79 <211> 73 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 79 tgaatggtcc caaaacggaa gggcctgagt ccgagcagaa gaagaagtttt tagagctatg 60 ctgttttgaa tgg 73 <210> 80 <211> 69 <212> DNA <213> Homo sapiens <400> 80 ctggtcttcc acctctgc cctgaacacc caatctcggc cctctcgcc acctcctgc 60 atttctgtt 69 <210> 81 <211> 138 <212> DNA <213> Mus musculus <400> 81 acccaagcac tgagtgccat tagctaaatg catagggtac cacccacagg tgccaggggc 60 ctttcccaaa gttcccagcc cttctccaa cctttcctgg cccagaggct ttcccatgtg 120 tgtggctgga cccttga 138 <210> 82 <211> 21 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 82 aaaaccaccc ttctctctgg c 21 <210> 83 <211> 21 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 83 ggagattgga gacacggaga g 21 <210> 84 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 84 ctggaaagcc aatgcctgac 20 <210> 85 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 85 ggcagcaaac tccttgtcct 20 <210> 86 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 86 gtgctttgca gaggcctacc 20 <210> 87 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 87 cctggagcgc atgcagtagt 20 <210> 88 <211> 22 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 88 accttctgtg tttccaccat tc 22 <210> 89 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 89 ttggggagtg cacagacttc 20 <210> 90 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 90 ggctccctgg gttcaaagta 20 <210> 91 <211> 21 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic primer" <400> 91 agaggggtct ggatgtcgta a 21 <210> 92 <211> 30 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic probe" <400> 92 tagctctaaa acttcttctt ctgctcggac 30 <210> 93 <211> 30 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic probe" <400> 93 ctagccttat tttaacttgc tatgctgttt 30 <210> 94 <211> 99 <212> RNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (1)..(20) <223> a, c, u, g, unknown or other <400> 94 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60 cguuaucaac uugaaaaagu ggcaccgagu cggugcuuu 99 <210> 95 <211> 12 <212> DNA <213> Homo sapiens <400> 95 tagcgggtaa gc 12 <210> 96 <211> 12 <212> DNA <213> Homo sapiens <400> 96 tcggtgacat gt 12 <210> 97 <211> 12 <212> DNA <213> Homo sapiens <400> 97 actccccgta gg 12 <210> 98 <211> 12 <212> DNA <213> Homo sapiens <400> 98 actgcgtgtt aa 12 <210> 99 <211> 12 <212> DNA <213> Homo sapiens <400> 99 acgtcgcctg at 12 <210> 100 <211> 12 <212> DNA <213> Homo sapiens <400> 100 taggtcgacc ag 12 <210> 101 <211> 12 <212> DNA <213> Homo sapiens <400> 101 ggcgttaatg at 12 <210> 102 <211> 12 <212> DNA <213> Homo sapiens <400> 102 tgtcgcatgt ta 12 <210> 103 <211> 12 <212> DNA <213> Homo sapiens <400> 103 atggaaacgc and 12 <210> 104 <211> 12 <212> DNA <213> Homo sapiens <400> 104 gccgaattcc tc 12 <210> 105 <211> 12 <212> DNA <213> Homo sapiens <400> 105 gcatggtacg ga 12 <210> 106 <211> 12 <212> DNA <213> Homo sapiens <400> 106 cggtactctt ac 12 <210> 107 <211> 12 <212> DNA <213> Homo sapiens <400> 107 gcctgtgccg ta 12 <210> 108 <211> 12 <212> DNA <213> Homo sapiens <400> 108 tacggtaagt cg 12 <210> 109 <211> 12 <212> DNA <213> Homo sapiens <400> 109 cacgaaatta cc 12 <210> 110 <211> 12 <212> DNA <213> Homo sapiens <400> 110 aaccaagata cg 12 <210> 111 <211> 12 <212> DNA <213> Homo sapiens <400> 111 gagtcgatac gc 12 <210> 112 <211> 12 <212> DNA <213> Homo sapiens <400> 112 gtctcacgat cg 12 <210> 113 <211> 12 <212> DNA <213> Homo sapiens <400> 113 tcgtcgggtg ca 12 <210> 114 <211> 12 <212> DNA <213> Homo sapiens <400> 114 actccgtagt ga 12 <210> 115 <211> 12 <212> DNA <213> Homo sapiens <400> 115 caggacgtcc gt 12 <210> 116 <211> 12 <212> DNA <213> Homo sapiens <400> 116 tcgtatccct ac 12 <210> 117 <211> 12 <212> DNA <213> Homo sapiens <400> 117 tttcaaggcc gg 12 <210> 118 <211> 12 <212> DNA <213> Homo sapiens <400> 118 cgccggtgga at 12 <210> 119 <211> 12 <212> DNA <213> Homo sapiens <400> 119 gaacccgtcc ta 12 <210> 120 <211> 12 <212> DNA <213> Homo sapiens <400> 120 gattcatcag cg 12 <210> 121 <211> 12 <212> DNA <213> Homo sapiens <400> 121 acaccggtct tc 12 <210> 122 <211> 12 <212> DNA <213> Homo sapiens <400> 122 atcgtgccct aa 12 <210> 123 <211> 12 <212> DNA <213> Homo sapiens <400> 123 gcgtcaatgt tc 12 <210> 124 <211> 12 <212> DNA <213> Homo sapiens <400> 124 ctccgtatct cg 12 <210> 125 <211> 12 <212> DNA <213> Homo sapiens <400> 125 ccgattcctt cg 12 <210> 126 <211> 12 <212> DNA <213> Homo sapiens <400> 126 tgcgcctcca gt 12 <210> 127 <211> 12 <212> DNA <213> Homo sapiens <400> 127 taacgtcgga gc 12 <210> 128 <211> 12 <212> DNA <213> Homo sapiens <400> 128 aaggtcgccc at 12 <210> 129 <211> 12 <212> DNA <213> Homo sapiens <400> 129 gtcggggact at 12 <210> 130 <211> 12 <212> DNA <213> Homo sapiens <400> 130 ttcgagcgat tt 12 <210> 131 <211> 12 <212> DNA <213> Homo sapiens <400> 131 tgagtcgtcg ag 12 <210> 132 <211> 12 <212> DNA <213> Homo sapiens <400> 132 tttacgcaga gg 12 <210> 133 <211> 12 <212> DNA <213> Homo sapiens <400> 133 aggaagtatc gc 12 <210> 134 <211> 12 <212> DNA <213> Homo sapiens <400> 134 actcgatacc at <210> 135 <211> 12 <212> DNA <213> Homo sapiens <400> 135 cgctacatag about <210> 136 <211> 12 <212> DNA <213> Homo sapiens <400> 136 ttcataaccg gc <210> 137 <211> 12 <212> DNA <213> Homo sapiens <400> 137 12 ccaaacggtt <210> 138 <211> 12 <212> DNA <213> Homo sapiens <400> 138 cgattccttc gt <210> 139 <211> 12 <212> DNA <213> Homo sapiens <400> 139 cgtcatgaat aa 12 <210> 140 <211> 12 <212> DNA <213> Homo sapiens <400> 140 agtggcgatg ac 12 <210> 141 <211> 12 <212> DNA <213> Homo sapiens <400> 141 cccctacggc ac 12 <210> 142 <211> 12 <212> DNA <213> Homo sapiens <400> 142 gccaacccgc ac 12 <210> 143 <211> 12 <212> DNA <213> Homo sapiens <400> 143 tgggacaccg gt 12 <210> 144 <211> 12 <212> DNA <213> Homo sapiens <400> 144 ttgactgcgg cg 12 <210> 145 <211> 12 <212> DNA <213> Homo sapiens <400> 145 actatgcgta gg 12 <210> 146 <211> 12 <212> DNA <213> Homo sapiens <400> 146 tcacccaaag cg 12 <210> 147 <211> 12 <212> DNA <213> Homo sapiens <400> 147 gcaggacgtc cg 12 <210> 148 <211> 12 <212> DNA <213> Homo sapiens <400> 148 acaccgaaaa cg 12 <210> 149 <211> 12 <212> DNA <213> Homo sapiens <400> 149 cggtgtattg ag 12 <210> 150 <211> 12 <212> DNA <213> Homo sapiens <400> 150 cacgaggtat gc 12 <210> 151 <211> 12 <212> DNA <213> Homo sapiens <400> 151 taaagcgacc cg 12 <210> 152 <211> 12 <212> DNA <213> Homo sapiens <400> 152 cttagtcggc ca 12 <210> 153 <211> 12 <212> DNA <213> Homo sapiens <400> 153 cgaaaacgtg gc 12 <210> 154 <211> 12 <212> DNA <213> Homo sapiens <400> 154 cgtgccctga ac 12 <210> 155 <211> 12 <212> DNA <213> Homo sapiens <400> 155 tttaccatcg aa 12 <210> 156 <211> 12 <212> DNA <213> Homo sapiens <400> 156 cgtagccatg tt 12 <210> 157 <211> 12 <212> DNA <213> Homo sapiens <400> 157 cccaaacggt is 12 <210> 158 <211> 12 <212> DNA <213> Homo sapiens <400> 158 gcgttatcag aa 12 <210> 159 <211> 12 <212> DNA <213> Homo sapiens <400> 159 tcgatggtaa ac 12 <210> 160 <211> 12 <212> DNA <213> Homo sapiens <400> 160 cgactttttg ca 12 <210> 161 <211> 12 <212> DNA <213> Homo sapiens <400> 161 tcgacgactc ac 12 <210> 162 <211> 12 <212> DNA <213> Homo sapiens <400> 162 acgcgtcaga ta 12 <210> 163 <211> 12 <212> DNA <213> Homo sapiens <400> 163 cgtacggcac ag 12 <210> 164 <211> 12 <212> DNA <213> Homo sapiens <400> 164 ctatgccgtg ca 12 <210> 165 <211> 12 <212> DNA <213> Homo sapiens <400> 165 cgcgtcagat at 12 <210> 166 <211> 12 <212> DNA <213> Homo sapiens <400> 166 aagatcggta gc <210> 167 <211> 12 <212> DNA <213> Homo sapiens <400> 167 cttcgcaagg on <210> 168 <211> 12 <212> DNA <213> Homo sapiens <400> 168 gtcgtggact ac <210> 169 <211> 12 <212> DNA <213> Homo sapiens <400> 169 ggtcgtcatc aa <210> 170 <211> 12 <212> DNA <213> Homo sapiens <400> 170 gttaacagcg tg <210> 171 <211> 12 <212> DNA <213> Homo sapiens <400> 171 tagctaaccg tt 12 <210> 172 <211> 12 <212> DNA <213> Homo sapiens <400> 172 agtaaaggcg ct 12 <210> 173 <211> 12 <212> DNA <213> Homo sapiens <400> 173 ggtaatttcg tg 12 <210> 174 <211> 15 <212> DNA <213> Homo sapiens <400> 174 cagaagaaga agggc 15 <210> 175 <211> 51 <212> DNA <213> Homo sapiens <400> 175 ccaatgggga ggacatcgat gtcacctcca atgactaggg tggtgggcaa c 51 <210> 176 <211> 15 <212> DNA <213> Homo sapiens <400> 176 ctctggccac tccct 15 <210> 177 <211> 52 <212> DNA <213> Homo sapiens <400> 177 acatcgatgt cacctccaat gacaagcttg ctagcggtgg gcaaccacaa ac 52 <210> 178 <211> 25 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (6)..(25) <223> a, c, t, g, unknown or other <400> 178 caccgnnnnn nnnnnnnnnn nnnnn 25 <210> 179 <211> 25 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <220> <221> modified_base <222> (5)..(24) <223> a, c, t, g, unknown or other <400> 179 aaacnnnnnn nnnnnnnnnn nnnnc 25 <210> 180 <211> 54 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 180 aacaccgggt cttcgagaag acctgtttta gagctagaaa tagcaagtta aaat 54 <210> 181 <211> 54 <212> DNA <213> Artificial Sequence <220> <221> source <223> / note="Description of Artificial Sequence: Synthetic oligonucleotide" <400> 181 caaaacgggt cttcgagaag acgttttaga gctatgctgt tttgaatggt ccca 54

Claims

1. 1. A method for identifying a unique target sequence in a eukaryotic genome for editing by CRISPR-Cas9, comprising: Locating protospacer adjacent motifs (PAMs) in the genome, where the PAMs are recognized by the Cas9 protein; Analyzing a target sequence upstream of the PAM, where the target sequence includes a 12 nucleotide seed region located immediately 5' to the PAM; and Seed: Selecting a target sequence where the PAM sequence occurs singly in the genome, thereby identifying a unique target sequence; The method includes:

2. 2. The method of claim 1, wherein the Cas9 protein is S. pyogenes Cas9 and the PAM is recognized by S. pyogenes Cas9.

3. 3. The method of claim 2, wherein the PAM is NGG.

4. 5'-N in the genome x -NGG-3', preferably wherein x is 20.

5. 5. The method of claim 4, comprising identifying a unique target sequence MMMMMMMMMNNNNNNNNNNNNNXGG, where NNNNNNNNNNNNNXGG has a single occurrence in the genome; where X is A, G, T, or C; N is A, G, T, or C; and M is A, G, T, or C.

6. 2. The method of claim 1, wherein the Cas9 protein is S. thermophilus CRISPR1 Cas9 and the PAM is recognized by S. thermophilus CRISPR1 Cas9.

7. The method of claim 6, wherein the PAM is NNAGAAW.

8. 5'-N in the genome x-NNAGAAW-3', preferably where x is 20.

9. 9. The method of claim 8, comprising identifying a unique target sequence MMMMMMMMMNNNNNNNNNNNNNNXXAGAAW, where NNNNNNNNNNNNNNXXAGAAW has a single occurrence in the genome; where W is A or T; X is A, G, T, or C; N is A, G, T, or C; and M is A, G, T, or C.

10. 2. The method of claim 1, wherein the Cas9 protein is S. thermophilus CRISPR3 Cas9 and the PAM is recognized by S. thermophilus CRISPR3 Cas9.

11. 11. The method of claim 10, wherein the PAM is NGGNG.

12. 5'-N in the genome x -NGGNG-3', preferably where x is 20.

13. 13. The method of claim 12, comprising identifying a unique target sequence MMMMMMMMMNNNNNNNNNNNNNXGGXG, where NNNNNNNNNNNNNXGGXG has a single occurrence in the genome; where X is A, G, T, or C; N is A, G, T, or C; and M is A, G, T, or C.

14. The method of any one of claims 1 to 13, wherein the target sequence upstream of the PAM is at least 20 bp in length.

15. The method according to any one of claims 1 to 14, wherein the genome is a mammalian genome or a human genome.